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Abstract   
Auger emitters gained significant interest in the past years due to the favorable suitability for 
target therapy at cellular level. Among Auger emitters, 
99m
Tc seems like the most appealing 
candidate for this task due to its great advantages regarding low cost, high availability and 
almost ideal radiochemical properties. The short range of Auger electrons demands that the 
radionuclide must be as close as possible to the target, usually the nuclear DNA, in order to 
cause significant therapeutic effects. Thus, the search for efficient delivery systems is the major 
challenge for Auger therapeutic applications. Radioactive complexes capable of entering the 
cell and target the nucleus showing affinity for the DNA molecule have been reported in the 
literature. Such compounds comprise efficient multifunctional chelators with the ability to 
stabilize the fac-[
99m
Tc(CO)3]
+
 core, as well as DNA-intercalating agents that ensure close 
proximity to the target. Herein we aimed to synthesize 
99m
Tc complexes (Tc1-4) stabilized by 
multifunctional chelators of the pyrazole-diamine type, containing anthracene (L1 and L2) or 
acridine orange (L3 and L4) as DNA-binding groups with longer (L2 and L3) or shorter (L1 and 
L4) spacer between the latter and the chelating agent. The corresponding Re complexes (Re1-
4) were also foreseen for full chemical characterization. Due to the demanding synthesis 
processes and available time, only Tc1 and Tc2 could be synthesized, characterized and 
biologically evaluated. The Re congeners showed ability to interact with the CT-DNA molecule 
trough spectroscopic studies. Tc1 and Tc2 also showed great ability to target the nucleus, once 
diffused into the cells of B16-F1 murine melanoma and PC3 human prostate cells, but no radio-
cytotoxic effect in these cell lines. Although efficient delivery system at subcellular level could be 
provided in this work, the relevance of the complexes for the design of Auger emitting 
99m
Tc 
radiopharmaceuticals could not be demonstrated. 
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Resumo 
A terapia com emissores Auger tem despertado interesse nos últimos anos devido à 
possibilidade de explorar terapia direccionadas, a nível celular. Entre os emissores Auger 
conhecidos, o 
99m
Tc oferece diferentes vantagens: baixo custo, elevada disponibilidade e 
propriedades radioquímicas favoráveis. O curto alcance dos electrões Auger constitui um factor 
limitante para a sua eficácia biológica exigindo que o radionucídeo se encontre o mais próximo 
possível do seu alvo, usualmente o DNA nuclear, de modo a exercer os seus efeitos 
terapêuticos. Assim, o maior desafio para o uso deste tipo de radionuclídeos em procedimentos 
terapêuticos é o desenho de vectores de entrega eficientes a nível subcelular. Já se encontra 
descrito um reduzido número de complexos radioactivos com capacidade de se localizar no 
núcleo das células e com afinidade para o DNA. Para esse efeito, tais compostos possuem em 
geral um agente quelante multifuncional com capacidade de estabilizar a unidade fac-
[
99m
Tc(CO)3]
+
 e, simultaneamente, um agente intercalador do DNA que assegura a proximidade 
e afinidade para o alvo. Neste trabalho propôs-se a síntese de complexos de tecnécio (Tc1-4) 
estabilizados por agentes quelantes do tipo pirazolo-diamina contendo os agentes 
intercaladores antraceno (L1 e L2) ou alaranjado de acridina (L3 e L4), com um espaçador 
metilénico maior (L2 and L3) ou menor (L1 and L4) entre o agente quelante e intercalador. 
Perspectivou-se ainda a síntese dos respectivos complexos de rénio (Re1-4) para uma 
completa caracterização dos compostos. Devido à elevada exigência da síntese dos ligandos e 
ao tempo disponível, apenas os complexos Tc1 e Tc2 foram sintetizados e caracterizados. 
Estudos espectroscópicos com os congéneres de Re mostraram que os complexos interagem 
com o DNA. Tc1 e Tc2 demonstraram elevada capacidade de se localizar no núcleo celular em 
estudos com células B16-F1 de melanoma de ratinho e células PC3 de cancro de próstata 
humana. No entanto, não exerceram qualquer efeito radio-citotóxico. Apesar de os complexos 
apresentarem uma elevada capacidade para atingir o núcleo de células tumorais, não foi 
possível demonstrar o seu interesse para o desenho de radiofármacos de 
99m
Tc para terapia 
Auger. 
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1 Introduction  
1.1 General aspects about Nuclear Medicine 
Nuclear Medicine is a specialized medical area for development and application of 
pharmacological agents (carrier) carrying radioactive atoms (radioisotopes) that emit 
penetrating and/or non-penetrating radiation. Both components, the carrier and the 
radioisotope, constitute the radiopharmaceutical agent and are determinant for its effectiveness. 
The characteristics of the carrier should provide tissue/organ specificity and good clearance 
from the organism, while the radionuclide should provide adequate amount and type of energy 
for the intended procedure. The different characteristics of the radiation emitted by the 
radioisotopes define if they can be applied for diagnostic or therapeutic purposes. However, a 
given radionuclides can be used to obtain therapeutic and diagnostic radiopharmaceuticals, and 
can also provide in vivo monitoring of therapeutic procedures. Its half-life (t1/2) is also very 
important for the data acquisition in diagnosis and for the dose-limiting in therapy.
1–3
 
Theranostics is another, very attractive, modality for the use of the radiopharmaceutical agents, 
as many radionuclides or matched/pairs of radionuclides have physical properties suitable both 
for imaging and therapeutic applications.  
Depending on the mode of their biodistribution, the radiopharmaceutical agents can be 
classified as perfusion or 1
st
 generation radiopharmaceuticals and target-specific or 2
nd
 
generation radiopharmaceuticals. The biodistribution of the former depends primarily on its 
physical-chemical properties such as charge, size and lipophilicity; while the latter are 
conjugated with a bioactive molecule (BM) that specifically recognizes and binds to its 
molecular target. Most of the available radiopharmaceuticals are perfusion agents but target-
specific radiopharmaceuticals are gaining more interest with the advances in molecular biology, 
and are more appealing for targeted procedures. 
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Figure 1.1 Representation of a target-specific or 2
nd
 generation radiopharmaceutical and its target
4
 
The targets for the target-specific radiopharmaceuticals are usually receptors but they can also 
be other biological entities. The BMs are referred as vehicle molecules and they can be enzyme 
substrates, agonists or antagonists for receptors and transporters or metabolites. A linker is 
usually used to minimize eventual structural-related changes in the properties and specificity of 
the BM with the introduction of the radionuclide. It can also be used as pharmacokinetics 
modulator of the final radiopharmaceutical.  
The final radiopharmaceutical should have good physical-chemical properties and 
pharmacokinetics, preferably with high metabolic stability; short but effective biological half-life, 
which represents the time needed for half of the radiopharmaceutical disappear from the 
biologic system; high specificity for the target and minimal accumulation in non-target tissue 
(ensured by the carrier); and should be easily produced with ready and cheap availability in 
clinical facilities (highly dependent on the t1/2 and availability of the radionuclide). If it is a 
radiotherapeutic agent it should also present emission of ionizing particles that can cause 
damage to the target biological system.
1,4,5
  
The use of radiopharmaceuticals for cancer diagnosis and/or therapy is of great interest. Early 
detection and targeted therapy can be provided (and possibly monitored simultaneously); 
however, as we will see throughout this thesis, it is a very demanding and complex process 
involving multiple areas such as molecular biology, organic and inorganic chemistry, 
biomedicine, etc.  
1.1.1 Diagnosis in Nuclear Medicine 
The big majority (> 90%) of the existing radiopharmaceuticals are for diagnostic applications, 
through molecular imaging procedures. This procedure is non-invasive and allows in vivo 
visualization of chemical and biological processes at cellular and molecular levels without 
interfering with its mechanisms. The trace quantity of the radiopharmaceutical used is not toxic 
for the living organism and allows image acquisition with good special resolution thanks to the 
available techniques. Unlike other imaging techniques as X-ray or ultrasound, where the images 
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are obtained through externally applied radiation, in Nuclear Medicine, the images are obtained 
by equipments that detect the tissue-penetrating radiation of the administrated (usually 
intravenously) radiopharmaceutical from the inside the body. Two imaging modalities, single 
photon emission computed tomography (SPECT) and positron emission tomography (PET) are 
the basis of Nuclear Medicine. These techniques are often coupled to computed tomography 
(CT) or to magnetic resonance imaging (MRI) to give hybrid imaging systems such as PET/CT, 
SPECT/CT or PET/MRI. This is because the SPECT and PET techniques have poor anatomic 
special resolution, contrary to the CT and MRI. The hybrid techniques provide acquisition of 
both anatomical and molecular/functional information with high resolution.
1–3,6
  
The radionuclides for PET imaging decay by emission of positron. This positively charged 
particle is annihilated by an electron in the matter originating two 511 keV γ-ray at opposite 
directions which are then detected simultaneously.  
Table 1.1 Commonly used β
+
 emitters for PET imaging
6
 
 
Two remarkable characteristics of the radionuclides used for PET imaging play important roles 
in radiopharmaceutical design. The first is the nature of the majority of these elements (see 
Table 1.1). In particular, the 
11
C, 
13
N and 
15
O isotopes are highly abundant in the biological 
systems and compose the majority of the molecules in the organism. This is a great advantage 
as these radionuclides can directly be incorporated in natural biomolecules without interfering 
with its biological properties. On the other hand, the second characteristic, which is the short 
half-lives of most of these radionuclides, is limiting for the efficacy and feasibility of the 
respective radiopharmaceuticals. The majority of these radionuclides are produced in 
cyclotrons, and along with the short half-lives, it is mandatory the presence of such equipments 
in or near to the clinical facilities, making PET imaging a very expensive procedure. Still, the 
11
C 
and 
18
F present reasonable properties and are widely used, and the exploitation of the more 
convenient metallic radionuclides such as 
64
Cu and 
68
Ga is gaining particular interest in 
PET.
1,2,4,6
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Table 1.2 Commonly used γ-ray emitters for SPECT imaging
6
 
 
The radionuclides for SPECT imaging are γ-photon emitters with an energy range about 30-300 
keV (minimal and maximum energies detectable using the commonly available collimators) with 
an optimal range around 150 keV. The collimator is positioned in front of the gamma camera 
and it defines the angle of incidence of the emitted γ-rays. In SPECT, the detection system is 
less sensitive and less efficient than in PET, thus presenting images with lower resolution. The 
major advantage for the use of SPECT over PET is the higher availability of suitable 
radionuclides, with longer half-lives at low cost. However, the SPECT radionuclides are mostly 
metallic elements (Table 1.2) requiring different and more difficult approaches for the synthesis 
of efficient radiopharmaceuticals compared to PET (see Section 1.3).
1,6
 
1.1.2 Therapy in Nuclear Medicine 
1.1.2.1 Biological effects of ionizing radiation 
Ionizing radiations lead to different ionizing events, when in contact with matter, which can 
cause damage to the cell molecules. The nuclear DNA is the most radiation-sensitive molecule 
of the cell, and the fact that it is determinant for the cell survival makes it its most valuable 
target. The DNA damage through ionizing radiation can occur by two processes: direct and 
indirect (Figure 1.2).  
1. Introduction 
[5] 
 
 
Figure 1.2 Direct vs indirect effects of ionizing radiation on DNA molecule
7
 
In direct effect the energy is directly transferred to the target molecule while in indirect effect 
an intermediate molecule is ionized leading to generation of highly reactive species which react 
with the target. The most important intermediate molecule for indirect effect is the extremely 
abundant H2O (about 80% of the cell mass) which produces reactive oxygen species (ROS), 
especially the hydroxyl radical (OH
.
), by radiolysis. It is estimated that the indirect effect occurs 
twice as much as the direct effect of radiation.
7,8
 
The main DNA lesions introduced by ionizing radiation are bases and sugar damage, single 
strand breaks (SSB) and double strand breaks (DSB). The damages can lead to cell death by 
necrotic or apoptotic activation pathways. The presence of scavengers or DNA-repair 
mechanisms may reduce significantly the potential of radiation damage. But they are not very 
effective for high radiation deposition which is associated with the direct effect and DSB lesions 
and present reduced rate of cell survival.
7
  
1.1.2.2 Systemic cancer therapy in Nuclear Medicine 
Cancer is one of the most common and challenging diseases of today’s society. The search for 
highly specific and efficient therapeutic agents is incessant with two major modalities: 
chemotherapy and radiotherapy. The reduced blood supply and biological transformation 
usually observed in cancer cells are limiting for systemic targeted therapy.
9
 Systemic 
radiotherapeutic procedures in Nuclear Medicine are still less developed, and the majority of the 
available radiopharmaceutical agents are yet at pre-clinical stage. This field is more challenging 
due to the poor availability of suitable therapeutic radionuclides and the need of developing 
highly specific delivery systems. The lack of specificity makes the determination of the 
administration dose a very difficult task.
5,10,11
 
Again, ideal radionuclides for therapeutic purposes must be highly available, with adequate t1/2 
and with abundance of particle/electron emission. The amount of the eventual accompanying 
penetrating radiation (such as γ-ray) must be minimal. There are three classes of suitable 
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radionuclides for therapeutic use: the α-emitters, β-emitters and Auger emitters. The 
overwhelming majority of the current radiotherapeutic agents in clinical use are β-emitters. Until 
recently, only α- and β-emitters radionuclides have been explored for therapeutic application 
(Table 1.3) but nowadays the potential of Auger electrons is gaining more attention.
3,10,12
 
Table 1.3 Examples of α- and β-emitters radionuclides for therapeutic applications
3
 
 
Besides the type of energy, the three classes of therapeutic radionuclides differ in the 
magnitude of the linear energy transfer (LET) and therefore in radiation range/penetration and 
biological effects. LET corresponds to the average energy deposition per unit distance along the 
path of the radiation and it is expressed as keV/ µm. The density of the energy deposition in 
biological tissue or cell determines the biological effectiveness of the radiation.
7
 
β-particles have low LET and long path length in order of millimeters, compared to the 20 µm 
diameter of the average cell. The biological effects are due to indirect effects. The LET of these 
particles is so low that the targeted therapy towards a specific macromolecule is not viable, 
because the energy deposition is not high enough to cause significant damage. The long range 
of β
-
 particles can be advantageous for the treatment of big metastases even if there is a non-
uniform drug distribution. The big disadvantageous is that there is an enhanced irradiation of the 
surrounding healthy cells.  
On the other hand, α-particles have high LET and very short range, in order of micrometers (30-
80 µm). It is suitable for treatment of metastatic cells with adequate blood supply at single-cell to 
a few cell-cluster levels. The major limitation for the application in therapy is the low availability 
of α-emitting radionuclides with adequate half-lives.
3,10,12
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Figure 1.3 Representation of the path lengh of the α-, β- and Auger radiation at cellular and subcellular 
levels. The Auger emitter requires close proximity to the target in order to have high biological 
effectiveness 
Similarly to the α-particles, Auger electrons present high LET but lower range, in order of 
nanometers (<100 nm), and very short penetration in biological systems. It is also suitable for 
the treatment of small metastases at single-cell level, preferentially by direct energy deposition 
on a cell target-component such as the DNA (Figure 1.3). Contrary to the case of β
-
 emitters, 
the high LET of α- and Auger emitters allow higher biological effectiveness by causing 
significant DSB through direct effect on the DNA molecule. The short range would provide a 
more efficient target therapy for the radiopharmaceuticals with minimal burden for the healthy 
tissue.
10,12
 
1.2 Auger electrons and cancer therapy  
1.2.1 Auger electrons  
Daughter nuclides in excited states may be generated after radioactive decay by the parent 
radionuclides. The de-excitation by isomeric transition (IT) to the ground state may occur by γ-
ray emission or by direct transfer of photons to an orbiting electron leading to its ejection in a 
process called internal conversion (IC) (Figure 1.4, left). This process creates a vacancy in the 
internal atomic shell. Another process that also generates this gap is the electron capture 
process in which an electron is transferred from the internal atomic shell into the nucleus.
1,7,10,13
  
In both cases the vacancy can be filled, followed by a cascade of electron transitions, by an 
electron of a higher electron shell. The energy difference between the two shells is released as 
photons by a radiative transition or as low-energy electrons (Auger electrons) by non-radiative 
processes (Figure 1.4, right). These electrons, named after the physicist Pierre Auger, are 
classified as Auger, Coster-Kroning or Super-Coster-Kroning if the filling and the ejected 
electrons come from a higher shell of the vacancy, if the ejected electron comes from a higher 
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shell but the filling electron comes from the same shell of the vacancy or if both the filling and 
ejected electrons came from the same shell of the vacancy, respectively. All these low-energy 
electrons are generally referred as Auger electrons.
10,13
  
 
Figure 1.4 Left: schematic representation of internal conversion (IC) process. The de-excitation of the 
radionuclide may occur by γ-ray or IC electron emission. The gap created can be filled by an electron of a 
higher electronic shell,  with energy release.
1
 Right: schematic representation of Auger electron emission. 
A gap in eletronic shell originated by IC or by electron capture is filled by an electron of a higher shell. The 
energy is transfrerred to another electron of the higher shell which is emitted. 
1.2.2 Prospective Auger emitters for cancer therapy 
The recent interest for Auger electron emitters in nuclear medicine is because α and β
-
 emitters 
failed as therapeutic agents for the treatment of small metastases due to the lack of ideal 
nuclides, low specificity or high potential for causing unwanted side effects. The therapeutic 
potential of Auger electrons was once neglected because of its short range, low penetration and 
low energy yield per decay. But since Carlson and White
14
 in 1963 demonstrated that the 
Auger-emitter 
125
I could cause molecular fragmentation, and with the advances in molecular 
biology, targeted therapy at subcellular level gained much interest and potentiated the 
exploitation of Auger emitting radiopharmaceuticals. The use of Auger electrons emitters for 
targeted therapy presents great advantages. The short range and high LET (4-26 keV/μm) 
provide high effectiveness in the irradiation of the target with low toxicity for the non-target 
molecules/cells.
10,13,15
  
The DNA is the main target for targeted therapy at subcellular level and most of the cancer 
therapeutic agents prevent or reduce tumor grow by interfering with the DNA integrity directly or 
through inhibition of DNA enzymes. The radiotoxicity of Auger electrons by indirect effect 
towards DNA molecule has been reported and it’s the most common effect caused by this type 
of particles.
15
 But the search for specific therapy via direct effect through DNA targeting is more 
appealing as the damage can be greater and difficult to repair. The biggest challenge relies on 
the development of efficient radioactive compounds able to ensure close proximity of the 
1. Introduction 
[9] 
 
nuclide to the molecule target and with high specificity and clearance from the body in order to 
reduce the dose limiting toxicity. This would provide administration of adequate doses without 
accumulation in non-target tissue and efficient tumor-cell killing as the absorbed doses tend to 
be non-uniform. In other words, this type of radiopharmaceuticals require uptake by all the cells 
of the tumor in order to exert its therapeutic functions.
13,16
 
Table 1.4 Examples of Auger electron emitters with potential interest for radiotherapy
10
 
 
Data from American Association of Physicists in Medicine (AAPM). The total energy per decay also 
includes γ and X-ray contributions. 
The efficiency of Auger emitter-based radiopharmaceuticals is also dependent on the 
characteristics of the radionuclide. As seen in Table 1.4, there are different Auger emitters of 
different chemical nature (halogens and metals) with different energy range and Auger electrons 
yield per decay. The IC electrons energies are presented separately because, despite being 
higher than those of most Auger electrons, IC electrons present low LET and high penetration 
(in μm range), thus presenting different biological effectiveness. Herein we only consider the 
Auger electrons for therapy at single-cell level. Other characteristics like half-lives, availability or 
suitability for functionalization are also critical for the use of such radionuclides. For example, 
55
Fe present one of the highest Auger electrons yield per decay but its t1/2 makes it unsuitable 
for clinical use.
10
 
The Auger emitters 
111
In, 
125
I, and
 123
I are already considered as potential therapeutic 
radionuclides showing great results in in vitro cytotoxic studies by causing DSB or SSB in DNA. 
The toxicity at single-cell level is comparable to that of α and higher than that of β radionuclides 
as the low LET of the latter provide predominantly non-specific irradiation effects.
13,17–19
 Still, the 
reduced availability (cyclotron produced radionuclides)
1
 is limiting for the use of these 
radioisotopes.  
It is known that the cytotoxicity induced by Auger electron emitters is significantly higher when 
the radionuclide is positioned as close as possible to the DNA. When located outside the cell 
nucleus, the cytotoxicity of the radionuclide is much reduced.
10
 An important study by 
Balagurumoorthy and co-workers evaluated the effect of the distance between the decaying 
Auger-emitter, 
125
I, and the DNA molecule on DSB yield.
20
 In this study, the correlation between 
Multifunctional Organometallic Compounds for Auger Therapy  
 
 
 
[10] 
 
the distance augmentation and the shift on the mechanism, as well as on the magnitude of DSB 
yield, was quite obvious. The evaluated compounds were derivatives of the DNA groove binder 
Hoechst 33258, which were labeled with the radionuclide 
125
I. The compounds only differed on 
the spacer size between the DNA binder and the radionuclide, which positioned the latter at 
different distances from the DNA molecule as estimated by molecular modeling. They noticed 
that in absence of the *OH scavenger dimethyl sulfoxide (DMSO), all the compounds were able 
to cause DSB although the DSB yield was lower for those compounds that placed the 
125
I at 
higher distances from the DNA. However, in the presence of DMSO, the DSB yield remained 
nearly unchanged for the compounds that ensured closer proximity of 
125
I to the DNA while the 
ones with higher 
125
I distances basically were not able to cause DSB. They concluded that for 
Auger emitters, the occurrence of direct effect requires a closer proximity at certain distance, 
even if the potential radiopharmaceutical is bound to the DNA target molecule. 
1.3 Design of metal-based radiopharmaceuticals  
As seen previously, there is available a large variety of metallic radionuclides with favorable 
features to be used in the development of diagnostic and/or therapeutic radiopharmaceuticals. 
For this reason, inorganic chemistry is an important area for the development of 
radiopharmaceuticals. In fact, most of the available radiopharmaceuticals are 1st or 2nd 
generation metal-based agents. The metallic radionuclides present great advantages because 
of its high availability at low cost, rich coordination chemistry and generally adequate 
characteristics such as half-lives, magnitude/type of the energy emitted or particle 
emission.
5,11,21
  
The major limitation for the use of these radionuclides is its incorporation into the pharmacologic 
agents to obtain specific and efficient final radiopharmaceuticals. For design of target-specific 
compounds, usually a bifunctional chelator (BFC) is needed to provide the attachment of the 
radiometal to the BM (Figure 1.5). 
 
Figure 1.5 Schematic representation of the bifunctional chelator (BFC) approach 
The choice of the BFC is dictated by the oxidation state of the radiometal and its affinity for the 
donor atoms of the chelating agent. The BFC approach must ensure tight bounding of the 
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radiometal to the carrier to obtain kinetically inert and termodinamically stable complexes to 
avoid unbundling or transchelation by the natural chelators, which would lead to accumulation in 
non-target tissue. It also must retain the specificity of the BM for its target, which is usually 
ensured by linkers of appropriate length to move away the BM from the radioactive metal. The 
synthesis of the BFC usually includes the functionalization with the BM before coordination with 
the radiometal. Both steps must be feasible with reasonable cost and production time, but the 
latter is limiting, meaning rapid complexation kinetics and high purity of the final radio-conjugate 
is needed for viable application. Thus, the BFC should provide versatility for chemical 
conjugation with both radiometal and BM and high selectivity for the radiometal.
2,5,11,21–23
 
1.4 Technetium  
1.4.1 Basic chemical and radiochemical aspects 
Technetium, from the Greek technetos (artificial), is the first artificially made chemical element 
by man before its discovery in nature. It was first predicted by Mendeleev in 1869 as a second 
row transition metal with the atomic number of 43 but only discovered in 1937 by Perrier and 
Segrè, from a molybdenum plate bombarded with deuterons accelerated in a cyclotron. This 
metallic element belongs to the group 7 of the Periodic Table, presenting eight different 
oxidation states (+7 to -1) and diverse coordination chemistry that allows coordination with 
several chelators or BFC ligand systems with different denticity.
24,25
   
At least thirty-five isotopes of Tc (
86
Tc-
120
Tc) have been identified  and none of them is stable.
26
 
The most relevant Tc radioisotope in Nuclear Medicine is the 
99m
Tc, being applied in over 70% 
of all procedures in this field. This metastable radionuclide has almost ideal nuclear properties 
for medical imaging and till date it has only been applied for diagnosis. 
99m
Tc emits a highly 
abundant 140 keV γ-ray (90%), very close to the optimal energy required for detection by the 
gamma cameras, hence providing images with high resolution (see Figure 1.6). This energy is 
ideal to penetrate biological tissue without overexposure of the patient to radiation. Also, the 
radiation from the daughter nuclide is not preoccupant as the β
-
 energy emission by the 
99
Tc is 
very low. What also contributes to the minimal exposure to the radiation dose is the short 6 
hours t1/2 of 
99m
Tc. However this t1/2 is long enough to enable the synthesis of the 
99m
Tc 
radiopharmaceutical, analytical control and purification, administration and imaging procedures 
in patients.  
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Figure 1.6 Schematic representation of SPECT imaging with the brain perfusion agent 
99m
Tc-ethyl 
cysteinate dimer (ECD, or Bicisate)  in patient. Right: molecular structure of ECD; Center: schematic 
representation of a gamma camera image acquisition; Left: SPECT image obtained 12 hours after ECD 
administration in a patient with a cerebral embolism (adapted)
27–29
 
The favorable features, together with  the ready and inexpensive availability of 
99m
Tc by elution 
of the 
99
Mo/
99m
Tc generator and introduction of kits that allow fast and effective synthesis of the 
radioconjugates (Figure 1.7), justifies the success of 
99m
Tc in diagnostic Nuclear 
Medicine.
1,25,30,31
   
 
Figure 1.7 Obtention of 
99m
Tc from a 
99
Mo/
99m
Tc generator followed by 
99m
Tc radiopharmaceutical 
preparation and administration in patient (adapted) 
30
 
A typical 
99
Mo/
99m
Tc generator consists of [
99
MoO4]
2-
 (molybdate) adsorbed on the top of an 
alumina (Al2O3) ion-exchange chromatographic column (Figure 1.7). The 
99
Mo decay results in 
accumulation of [TcO4]
- 
(pertechnetate) until an equilibrium is reached, after approximately four 
half-lives of 
99m
Tc, at the maximum activity. The pertechnetate on top of the column is then 
eluted with a 0.9% NaCl solution and collected as [Na
99m
TcO4] (sodium pertechnetate). The 
molybdate stays retained in the column and the 
99
Mo decay originates more pertechnetate that 
can be eluted successively.  
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Scheme 1.1 Simplified scheme of 
99
Mo/
99m
Tc generator nuclear decays (adapted)
31
 
Scheme 1.1 summarizes the relationship between the nuclear decay of the radionuclides 
present on the 
99
Mo/
99m
Tc generator. 
99
Mo decays with a half-life of 66 hours by β
- 
emission to 
99m
Tc (≈87%) and 
99
Tc (≈13%). The metaestable 
99m
Tc (t1/2 = 6h) decays by isomeric transition 
of 140 keV to the ground state 
99
Tc (t1/2 = 2.1 x 10
5 
years) which decays to the stable 
99
Ru by β
-
 
emission.
1,30,31
 
The concentration of [TcO4]
-
 obtained from each elution is usually about 10
-7
 to 10
-10  
M, thus the 
synthesis of the radiopharmaceutical agents has to be done directly from the eluate aqueous 
solution. As the 
99m
TcO4
-
 is at +7 oxidation state it first has to be reduced to lower oxidation 
states by adequate reducing agents under adequate reaction conditions (temperature, pH, etc.), 
in order to react with the ligands to produce the radiopharmaceutical agent. The final 
99m
Tc 
oxidation state determines the choice of the donor atoms and denticity of the chelator, as well 
as the type of metallic core.
25
 Several different cores with different oxidation states and ligands 
of different denticity were used to obtain a variety of 
99m
Tc agents applied in diagnostic imaging 
of brain, skeleton, heart, lung, bone marrow, infection, inflammation, etc., as described in the 
literature.
25,29,31–33
 Some examples of the current approved 
99m
Tc-radiopharmaceuticals for 
kidney, brain and heart imaging can be seen in Figure 1.8. 
 
Figure 1.8 Molecular scrutures of some of the currently approved perfusion
 99m
Tc-radiopharmaceuticals
29
 
Tc(V) complexes used to be the most widely explored for the design of 
99m
Tc 
radiopharmaceuticals. However, lower 
99m
Tc oxidation states such as the Tc(I) are gaining more 
interest especially with the introduction by Alberto et al, 1998, of the novel fac-
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[
99m
Tc(H2O)3(CO)3]
+
 precursor, which can be obtained directly from [TcO4]
-
. Initially, the 
synthesis of this precursor was performed with the reducing agent NaBH4 under 1 atm of CO.
34
 
This method is not very feasible as the gaseous CO source is considered toxic and also limiting 
for the fast and ready availability of the precursor in commercial radiopharmaceutical kits. Today 
this problem is overcome by the use of a boranocarbonate reducing agent K2[H3BCO2] that 
works, simultaneously, as a source of CO for the precursor (see Scheme 1.2).
35
 The available 
kits allow fast (20-30 min) preparation of the tricarbonyl precursor in aqueous solution with high 
yield (>95%), in a single step. 
 
Scheme 1.2 Aqueous-based kit preperation of fac-[
99m
Tc(H2O)3(CO)3]
+
 precursor by Alberto et al, 2001
36
 
The fac-[
99m
Tc(H2O)3(CO)3]
+
 precursor is air and water stable in a broad range of pH (1-13) for 
hours.
34
 It is an octahedral complex with three CO ligands facially coordinated to the metal 
center and each one trans to a water molecules. The water molecules are highly labile and can 
easily be substituted by a variety of functional groups of different mono, bi or tridentate ligands, 
while the carbonyl groups are strongly bound to the metal center enabling stable and inert fac-
[
99m
Tc(CO)3(ligand)] complexes.
34,36
  
Although none radiopharmaceutical containing the fac-[
99m
Tc(CO)3] core has yet been applied in 
clinical trial, this core is of great interest due to the small and compact size, possibility of being 
stabilized with a large variety of ligand systems, which allows the formation of complexes with 
tuned physical-chemical properties, namely in terms of hydrophilicity and lipophilicity.
36
  
The characterization of the 
99m
Tc compounds is a limited process due to the very low 
concentration of this nuclide in aqueous solution. The only method sensitive enough to analyze 
these much diluted compounds is the HPLC (or other chromatographic methods) coupled to a 
γ-radiation detector. Otherwise only by use of 
99
Tc nuclide it is possible to perform the 
characterization with conventional analytical methods such as NMR, mass spectrometry (MS) or 
X-ray crystallography. The comparison of the HPLC chromatograms of the 
99m
Tc compounds 
with respective 
99
Tc counterparts allows their chemical identification.
25,30,31
 
99
Tc is a long-lived isomer of Tc, being the most abundant technetium radioisotope. It is 
available in macroscopic amounts, and is the most significant byproduct of 
235
U fission. 
99
Tc is a 
weak β
-
 emitter (0.292 MeV) with no accompanying γ-radiation, thus the HPLC studies of 
99
Tc 
compounds are performed using UV and β
-
 detection. The handling of 
99
Tc still has to be 
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performed under good laboratory practices, using glassware to block the β
- 
particles and taking 
appropriate precautions.
25,30,31
 
The chemical identification of 
99m
Tc complexes can be done by HPLC comparison with Re 
congeners, in alternative to the use of 
99
Tc compounds. The use of non-radioactive Re as 
99m
Tc 
analogous is advantageous as it is easier to manipulate without major precautions. The HPLC 
studies of Re complexes usually involves UV detection. 
Rhenium also belongs to the group 7 of the Periodic Table, with atomic number of 75 (Figure 
1.9), thus having rich coordination chemistry comparable to that of technetium. The existence of 
rhenium element, named after the river “Rhine”, was confirmed by Noddack-Tacke in 1925 by 
X-ray spectroscopy. Soon, this element was being produced in macroscopic scale.
24
  Re is one 
of the rarest elements in nature, consisting of a mixture of two isotopes, 
185
Re (37.4%) and 
187
Re (62.6%).
31
 Due to the lanthanide contraction, the chemistry of Tc and Re is very similar 
and the respective complexes present similar physical properties, such as size and lipophilicity. 
Nevertheless, some differences have to be taken into consideration. The technetium 
compounds are easier to reduce providing faster complexation reactions with the ligands. The 
rhenium complexes on the other hand are easier to oxidize and more kinetically inert providing 
more stable complexes.
31,36
  
 
Figure 1.9 Section of the Periodic Table with the group 7 elements Tc and Re  
Rhenium possesses two important radioactive isotopes, 
188
Re (t1/2 = 17 h; β
-
, 2.1 MeV) and 
186
Re (t1/2 = 90 h; β
-
, 1.1 MeV), which can be obtained by elution of the 
188
W/
188
Re generator or 
by neutron irradiation of 
185
Re, respectively. These metallic radioisotopes have great interest in 
Nuclear Medicine and are being explored based on coordination or organometallic complexes 
similar to those of the congener 
99m
Tc, in terms of available cores and chelators.
30,31,37
  
1.4.2 99mTc and cancer theranostics 
The capabilities of 
99m
Tc for in vivo imaging are well established being approved a large number 
of 
99m
Tc radiopharmaceuticals for diagnostic applications, as mentioned in the previous 
sections. By contrast, the potential of this radionuclide for clinical therapeutic applications 
remains to be demonstrated. For this reason, much attention has been drawn in recent years to 
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the evaluation of the potential therapeutic properties of this radionuclide, as is the case of the 
present thesis. In particular, these studies intend to prove the relevance of 
99m
Tc for 
Theranostics, which requires the combination of diagnostic and therapeutic capabilities in the 
same entity. 
As seen in Section 1.2.2 - Table 1.4, the 
99m
Tc nuclide is not the most promising Auger emitter 
candidate for therapy in terms of yield per decay. 
99m
Tc decays by isomeric transition 
predominantly by γ-ray emission and the total energy per decay is about 142.6 keV, where only 
0.6% of this energy is due to Auger emission and 10.8% due to IC. The number of IC and Auger 
electrons per decay are about 1.1 and 4, with energies around 15.4 and 0.9 keV, respectively. 
Only few studies have shown results that indicate some potentiality of this radionuclide for the 
development of therapeutic agents. Yet, the search is constant and motivated by the fact that 
along with all the advantages of using an Auger emitter for targeted therapy, 
99m
Tc is the most 
easily available at low cost among all the known Auger-emitting radionuclides. The cheap and 
ready availability, versatility, ideal t1/2 and the possibility to monitor the treatment through high 
resolution imaging are highly favorable characteristics of 
99m
Tc. The fact that 
99m
Tc is widely 
used in diagnosis, being available a large number of approved radiopharmaceuticals obtained 
with a variety of chelators and based on a well established radiochemistry, also facilitates the 
development of new and more efficient radiopharmaceutical agents.
10,13
 These favorable 
features prompted several research groups to evaluate 
99m
Tc complexes as potential 
radiopharmaceuticals for Auger therapy of cancer. Some of the most important results of such 
research work are presented bellow.  
The first reported in vitro study involving pertechnetate as a radiocytotoxic agent was performed 
with a bacterial strain of Escherichia coli, K12S, by Silva and co-workers in 1998. The studies 
consisted on two assays where the bacteria were directly (in growth medium) or indirectly 
(separated by glass-wall) exposed to [
99m
TcO4]
-
. The glass attenuates efficiently the Auger and 
IC electrons but not the γ-rays. They have noticed that the cells directly exposed to [TcO4]
-
 
presented significant reduced survival fraction relative to the ones exposed only to gamma 
radiation (5.6 and 65% respectively, after 180 min incubation with a 37mBq/mL final activity). 
Thus, they concluded that the Auger and/or IC electrons were responsible for the cell 
cytotoxicity rather than the gamma radiation of the 
99m
Tc decay. The high radio-cytotoxic effect 
in this case might be because there is greater access to the DNA in prokaryotes. Also, they 
showed that the introduction of free radical scavengers or metal ion chelators protected the cells 
against the radiotoxic effects of the 
99m
Tc decay indicating that these effects occur partially 
through indirect mechanisms.
38
  
In year 2000, Pedraza-López and co-workers reported in vitro DNA damage induced by 
99m
Tc-
radiopharmaceuticals incorporated in murine lymphocytes, as checked by single-cell gel 
electrophoresis. The cells were incubated with 
99m
Tc-hexamethyl-propylene amine oxime 
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(
99m
Tc-HMPAO) and 
99m
Tc-2,5-dihydroxybenzoic acid (
99m
Tc-gentisic acid). As expected, the 
99m
Tc-HMPAO diffused into the cytoplasm (19.6%; with final activity ≈ 5.3 Bq per cell) while the 
99m
Tc-gentisic acid remained bonded to the cell membrane (25.6%; with final activity ≈ 4.0 Bq 
per cell). Despite DNA breaks and alkali labile sites were observed in almost 100% of the cells, 
no cytotoxic effect was noticed. The results are consistent with the fact that, although the radio-
conjugates were close to the nucleus, as it occupies a large part of lymphocyte cells, this 
proximity was not enough to cause solid and irreparable DNA damages.
39
 
The first in vivo study showing cancer therapy properties of 
99m
Tc was performed with 
pertechnetate, which was administred to nude mice carrying NIS (sodium/iodide symporter)-
expressing neuroendocrine tumor, as reported by Behr and coworkers in 2007. They showed 
that the volume of the tumors decreased significantly in the presence of the radioactive 
compound, indicating potentiality of the this Auger emitter in therapy.
40
 More recently, 
successful studies with 
99m
Tc incorporated in multifunctionalized gold nanoparticles provide an 
extending on the use of this nuclide as a targeted therapeutic agent, through a variety of 
approaches and delivery systems.
41
  
The earlier studies did show that the Auger electrons emitted by 
9m
Tc can induce DNA damage 
but mainly emphasized the need for new complexes with the ability to target the cell DNA, in 
order to function as efficient therapeutic agents. Alberto and co-workers have pioneered the 
studies with such complexes by introducing multifunctionalized 
99m
Tc compounds with the ability 
to target the cell nucleus and enhanced radiotoxic effects in eukaryotic cells. First they 
synthesized two 
99m
Tc(I) complexes containing the fac-[
99m
Tc(CO)3] core coordinated by a 
triamine ligand, and functionalized with two different DNA binders, pyrene and anthraquinone 
(Figure 1.10). They evaluated the ability of these complexes to cause DSB as an indicator of 
cytotoxicity.
12
 
 
Figure 1.10 
99m
Tc-tricarbonyl complexes containing pyrene (left) or anthraquinone (right) DNA-binding 
groups
12
 
The complexes induced significant amount of DSB on a ɸ174 double-stranded DNA contrary to 
the non-DNA-binding [
99m
TcO4]
-
 and the respective non-radioactive Re compounds. The Re 
analogues were also used to evaluate the complexes interaction with the DNA molecule and 
showed that pyrene and anthraquinone complexes were able to interact with DNA. The authors 
concluded that the Auger electrons from the 
99m
Tc decay can induce DSB on DNA when located 
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in its direct vicinity. To evaluate the cytotoxicity at cellular level, they functionalized the pyrene-
containing 
99m
Tc complex with the SV40 nuclear localization sequence (NLS) peptide to allow 
nuclear targeting and hence, the proximity to the DNA molecule.
42
 They showed that the 
complex was able to accumulate in the nucleus of B16-F1 murine melanoma cells and induce a 
dose-dependent radiotoxic effect much more significant compared to that of non-nucleus/DNA-
targeting complexes (such as [
99m
TcO4]
-
). The cytotoxic effects through DNA damage were 
evident by the necrotic cell death through mitotic catastrophe pathway. Still, the doses of 
99m
Tc 
radioactivity applied were too high with small/slow uptake, which can be limiting for the use of 
this radionuclide in therapy. This problem had to be overcome by the use of efficient delivery 
systems that can provide both fast and high uptake by the cells in order to minimize the applied 
doses.  
In another study, Alberto and coworkers found out that related tricarbonyl M(I) (M = 
99m
Tc, Re) 
complexes bearing acridine orange as DNA-binding group were able to target the nucleus of 
B16-F1 and PC3 human prostate cancer cells without the presence of the NLS peptide.
43
 The 
complexes functionalized with a bioactive peptide bombesin (BNN) showed high specific uptake 
by the PC3 cells through receptor-mediated mechanisms but were not able to reach the 
nucleus. All the results together indicate that an efficient therapeutic 
99m
Tc radiopharmaceutical 
has to be at least functionalized with a DNA-binding group, a NLS and a tumor seeking-vector. 
Another option is the so-called [2 +1] approach, where the bioactive peptide could be released 
once inside the cell, while the 
99m
Tc complex would then reach the nucleus without the presence 
of the NLS.
44
 
 
Figure 1.11 Re-tricarbonyl complexes containing acridine orange as  DNA-binding group (left) 
functionalized with bombesin (BBN) bioactive peptide (right) introduced by Alberto and coworkers
43
  
The group of Ciências Radiofarmacêuticas (CR) from C
2
TN – IST, where the experimental work 
on the basis of this MSc thesis has been performed, has also been involved in the study of 
multifunctional 
99m
Tc tricarbonyl complexes for specific targeting of the nucleus of cancer cells, 
as summarized below.
45–48
  
Victor et al, 2008, verified by fluorescence microscopic studies that two novel Re(I) complexes 
containing the fac-[ReCO)3]
+
 core and an anthracenyl pyrazole-diamine ligand were able to 
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target and enter the nucleus of B16-F1 murine melanoma cells. The characterization of the DNA 
interaction of these complexes by different spectroscopic techniques has shown a moderate 
affinity of the compounds towards CT-DNA. Later, in 2009, the authors synthesized the 
congener complexes with 
99m
Tc and demonstrated that the complexes were also able to enter 
the nucleus of B16-F1 cells, causing in some cases significant radio-cytotoxic effects and cell 
death. Most importantly, the radiotoxicity found for these anthracenyl-containing pyrazolyl-
diamine 
99m
Tc(I) tricarbonyl complexes containing against B16F1 murine melanoma cells was 
well correlated with their nuclear uptake. The 
99m
Tc complex having the anthracenyl group at the 
4- position of the azolyl ring (complex Tc1, Figure 1.12 (right)) showed the highest radio-
cytotoxicity and induced cell death apparently through caspase-3 apoptotic pathways.  
 
Figure 1.12 
99m
Tc-tricarbonyl complexes containing anthracene DNA-binding group at terminal amine of 
the pyrazole-diamine chelator (left) or at 4-position of the pyrazolyl ring  (right) introduced by Vitor et al
48
  
Esteves et al (2010) have introduced a pyrazole-diamine 
99m
Tc(I) complex bearing acridine 
orange (AO) as a DNA binding group, using a butylenic spacer to attach the AO to the 4- 
position of the pyrazolyl ring. The authors showed that this complex was also able to target the 
nucleus of B16-F1 cells. Moreover, Esteves et al (2011) further functionalized the AO containing 
99m
Tc(I) complex with the bombesin analogues SGS-BNN and GGG-BNN as tumor-seeking 
peptides. The Re and 
99m
Tc complexes containing the GGG-BNN showed high cellular 
internalization and nuclear uptake in PC-3 cells expressing the GRP-receptor (see Figure 1.13). 
The observed cell uptake was receptor-mediated showing that the presence of the metal-
complexes and/or DNA intercalator did not compromise the ability of specific cell targeting by 
the BBN vector. Another interesting result is the fact that the GGG-BNN complex can still reach 
the nucleus, most probably following the lysosomal degradation of the BBN peptide. These are 
the first examples of 
99m
Tc complexes that can simultaneously have specific cell targeting and 
nuclear internalization, a quite encouraging result to further explore this class of compounds in 
the design of radiopharmaceutical agents for Auger therapy of cancer. But, unlike the Tc1 
introduced by Vitor, the new complexes do not display radio-cytotoxic effects. 
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Figure 1.13 Left: Molecular structure of Re-tricarbonyl complexes containing acridine orange DNA-binding 
group at 4-position of the  pyrazolyl ring and functionalized with bombesin analogues. Right: Single-cell 
fluorescence distribution of the Re-complexes in PC-3 cells, visualized by time-lapse cofocal microscopy 
imaging at time points of 5, 15, 30 and 60 min.
47
 
1.5 Background and aim of the thesis  
As mentioned before, the potential capability of 
99m
Tc-labeled compounds to simultaneously 
function as therapeutic and diagnostic chemical entities has gained interest in recent years. To 
explore this potential quality, also known as theranostic property, several complexes have been 
synthesized and characterized chemically and biologically. For this purpose, the major 
challenge is to obtain compounds with selective uptake by tumor cells and with the ability to 
interact with its nuclear DNA, thus leading to cell death as a result of DNA damage induced by 
Auger electrons emitted by 
99m
Tc. As this radionuclide is a gamma emitter as well, it could also 
be possible to monitor the treatment with such complexes using SPECT techniques in patients. 
Despite some promising in vitro results that have been reported, to date there is no example of 
99m
Tc that has fulfilled the necessary requisites to be used in theranostic applications, 
particularly in Auger therapy of cancer. 
Following some of the previous studies started by the CR group and inspired by several other 
studies in this field; in this project it was aimed to synthesize, characterize and evaluate 
biologically 
99m
Tc(I) tricarbonyl complexes stabilized by pyrazole-diamine units functionalized 
with two different DNA-binding moieties, anthracene or acridine orange. In particular, it was 
intended to test the effect of the distance between the decaying 
99m
Tc and the intercalator on 
the DNA damage and radio-cytotoxicity induced by the radiocomplexes. For these studies, it 
was decided to further evaluate the best performing complex introduced by the CR group, i.e. 
Tc1 (see Fig. 1.12) extending its in vitro biological evaluation to PC-3 human prostate cancer 
cells, and compare its biological performance with related complexes having anthracene or AO 
1. Introduction 
[21] 
 
groups as DNA binders and different linkers to attach these groups to the pyrazolyl ring (see 
Figure 1.14).  
 
Figure 1.14 Molecular structures of the Re and 
99m
Tc complexes  proposed in this thesis 
After identifying the best performing complex from those proposed in Figure 1.14, a next step 
would be its functionalization with a bioactive peptide (BM), such as bombesin, and a NLS, as 
proposed in Figure 1.15.  The multi-functionalization with a NLS along with the tumor-seeking 
vector should improve the ability of the complexes to target the nucleus of tumor cells, in close 
proximity with DNA, which is a crucial issue to explore 
99m
Tc in Auger therapy.  
 
Figure 1.15 Schematic representation of 
99m
Tc radiopharmaceuticals intended with this thesis 
 
Multifunctional Organometallic Compounds for Auger Therapy  
 
 
 
[22] 
 
Briefly, a 
99m
Tc compound that can combine specific cell targeting, nuclear internalization and 
significant cell killing due to the Auger electron effect is yet to be introduced. Herein, it was 
intended to contribute for a better understanding of the structural characteristics (e.g. nature of 
DNA binder, spacer length, presence of NLS and/or bioactive peptide) that are more 
determinant of their ability to induce DNA damage and cause radiotoxic effects against tumor 
cells.  
1.6 Rationale for the design and evaluation of the proposed complexes 
1.6.1 Pyrazole-diamine BFCs 
A large variety of mono, bi or tridentate N, S, P or O-donor ligands can stabilize the fac-
[M(CO)3]
+
 (M = Re, Tc) core.
49–52
 Pyrazole derivatives are very versatile, have been widely used 
for biomedical applications and in some cases can also coordinate this organometallic core.
53
 
Mono and bidentate chelators give M(I) (M = Re, Tc) tricarbonyl complexes that show reduced 
in vivo and in vitro stability. By contrast, it has been established that tridentate NNN-donor 
ligands give more stable complexes.
51
 In fact, various studies showed that pyrazole-diamine 
(pzNN) ligands are ideal tridentate BFCs for the stabilization of fac-[M(CO)3]
+
, leading to 
complexes with high kinetic inertness and thermodynamic stability that are obtained  in high 
specific activity, with high yield and radiochemical purity,.
45–52,54
 Pyrazolyl-diamine chelators 
provide three N donor atoms with great capacity to replace the water molecules of the fac-
[M(CO)3]
+
 (M = Re, Tc)  core. More details about its coordination chemistry can be found 
elsewhere.
49,50
   
 
Figure 1.16 Schematic representation of different possibilities for functionalization of pyrazole-diamine 
BFCs with biomolecules and/or DNA-binding groups. The N donor atoms for stabilization of fac-[M(CO)3]
+
 
are also featured. 
The versatility of pyrazolyl-diamine ligands makes them suitable for functionalization with BMs 
and/or other relevant organic compounds through the amines or the pyrazolyl ring (Figure 1.16). 
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So far, the reported studies showed that their coordination capability towards the fac-[M(CO)3]
+
 
(M = Re, Tc) is not affected by their functionalization with BMs or DNA. Usually, the resulting 
radio-conjugates have great in vitro and in vivo stability, and still retain its biological 
functions.
49,50,52,54
 Favorable pharmacokinetics (i.e. fast clearance from the blood, minimal 
retention in the hepatobiliary tract and kidneys with rapid urinary excretion) have also been 
reported in mice for several pyrazole-diamine 
99m
Tc tricarbonyl complexes bearing bioactive 
peptides, such as bombesin or melanocortin analogues.
52,55
 
Herein, we will use pyrazole-diamine ligands containing anthracenyl or AO groups, as DNA 
binders that are introduced at the 4- position of the pyrazolyl ring using appropriate linkers. 
Then, the secondary amine can be used for further functionalization with the BBN analogue and 
with a nuclear localization sequence (NLS).
47,52,54
  It is worthwhile to mention that in the case of 
anthracene derivatives of pyrazolyl-diamine ligands it has been shown that the corresponding 
99m
Tc complexes have higher nuclear uptake and enhanced radio-cytotoxic effects on B16-F1 
murine melanoma cells when the DNA binder is attached through the azolyl ring, if compared 
with the complexes having the anthracenyl group at the terminal amine. Studies of the 
interaction of this type of anthracenyl-containing ligands and their Re complexes with calf 
thymus (CT) DNA showed that the position used to introduce the DNA binder also influences 
the way how the compounds interact with DNA.  
1.6.2 DNA-binding groups and DNA interaction 
As said before, for Auger therapy it is mandatory that the radionuclide stays as close as 
possible to the target DNA in order to cause a significant damage by direct effect of the Auger 
electrons. By functionalization of the chelate with an aromatic DNA-binding group it is expected 
that once inside the cell nucleus, the radio-conjugate will be able to have a strong interaction 
with DNA and provide an enhancement on the radio-cytotoxicity effect by the short-ranged 
Auger electrons. The introduction of aromatic DNA-binding group in 
99m
Tc radiopharmaceuticals 
is also very convenient, as its fluorescence properties allow in vitro studies with the Re 
congeners by different microscopy techniques, at cellular and subcellular level where the in vivo 
imaging by 
99m
Tc has very poor resolution.
43
 
DNA-targeted therapy is gaining much interest and a couple of anticancer, antibacterial or 
antiviral drugs bearing small molecules capable of interacting with DNA have been intensively 
studied.
56–58
 The information about how these molecules interact with the DNA - the binding-
mode, kinetics and the forces involved - is crucial to understand and predict the effects they will 
have, thus potentiating their use for biomedical applications. Some molecules interact with the 
DNA in a very specific way and it is important to take in consideration that this interaction is 
dependent on certain characteristics like its size, structure and charge.
56,59,60
 So, the 
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conjugation with other entities more likely will change, slightly or drastically, the way this 
interaction occurs. Therefore, it is important to determine the binding mode of the DNA-binding 
moiety as well as of the whole conjugate. 
1.6.2.1 DNA binders and DNA-binding modes 
The structural conformation of DNA is very diverse, which allows the interaction with a variety of 
small molecules in various specific and non-specific different ways. The most important 
interaction modes for the design of drugs containing DNA-binding molecules are intercalation 
and groove binding
56–60
, where the minor groove binding is the predominant among the DNA-
binding drugs
58
 (Figure 1.17). These binding modes are non-covalent and reversible most of the 
times. The drugs with this type of interaction are usually less toxic than the ones with covalent 
binding mode.
61
 
 
Figure 1.17 The three main binding modes of small molecules with the DNA with biomedical interest for 
drugs containing DNA-binding units (A-intercalation; B-minor groove binding; C-major groove binding) 
Intercalators are usually planar fused hetero-aromatic molecules that insert, partially or entirely, 
between adjacent base pairs of the DNA inducing structural changes. Some non-fused aromatic 
rings were found capable of intercalating the DNA base pairs and are classified as atypical 
DNA-intercalators.
57
 The interaction is stabilized mainly by van der Waals forces and 
hydrophobic interactions and, depending on the charge of the molecule, might include hydrogen 
bonding or ionic forces involving the negatively charged DNA phosphate groups.
56–60
 All these 
contributions lead to favorable intrinsic binding constants (K) that compensate the free energy 
cost of this type of interaction.
57
  These type of DNA-binders do not have sequence-specific 
recognition sites but usually prefer the CT-rich sequences and alternating purine-pyrimidine 
sequences.
58
 
The groove binders generally don’t cause perturbation on the DNA structure. They are mostly 
minor groove binders composed by non-fused aromatic rings with terminal base functions and a 
narrow curved shape. The interaction is also stabilized by intermolecular interactions but without 
any free energy cost and therefore a higher intrinsic binding constant.
57
 The elected sequence-
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specific sites are the AT-rich sequences because of the favorable hydrophobic contacts and 
accessibility of hydrogen bond receptors.
56,58
 
 
Figure 1.18 Molecular structure of some DNA-binding molecules
56,57
 
Figure 1.18 shows the molecular structure of two of the most widely studied DNA-binders: the 
DNA-intercalator ethidium bromide and the DNA-minor groove binder Hoechst 33258. The 
structures of methapyriline and the mitomycin are also presented as examples of structurally 
atypical intercalator and groove binder, respectively.  
1.6.2.2 Acridine orange and anthracene  
Acridine was the first proposed model molecule for the study of ligand-DNA interaction by 
Lerman in 1961.
62
 It is a versatile planar polyaromatic structure related to anthracene that 
allows several chemical reactions and acts as a classic DNA intercalator. Its potential as anti-
tumor agent has been intensively explored, with a variety of molecular manipulations to 
enhance the therapeutic effects and overcame its high cytotoxicity. Acridine and its derivatives 
are very important for biomedical applications and several therapeutic agents based on these 
molecules have been developed.
63,64
 The cationic derivative acridine orange (AO) (Figure 1.19) 
is no exception with enhanced electrostatic attraction towards the phosphate group of the DNA. 
It usually provides drugs with high affinity and specificity for the DNA molecules with good 
stability and solubility in aqueous solution. The high absorption capacity, fluorescence intensity 
and staining properties make this molecule and its conjugates suitable for a variety of studies by 
the available spectroscopic and optical techniques.
65
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Figure 1.19 Molecular structures of acridine orange and antracene 
Anthracene (Ant) is a large planar hydrophobic polyaromatic hydrocarbon constituted by three 
fused benzene rings (Figure 1.19). Its chemical versatility allows the functionalization with other 
entities and thus the alteration of its chemical and physical properties, like hydrophobicity. It is a 
DNA intercalator but when conjugated with other molecules its properties tend to change 
significantly. Yet, its derivatives and conjugates generally retain its remarkable fluorescence and 
absorption characteristics.
66,67
 
The use of these two different DNA-binding groups, AO and anthracene, with different 
properties and affinity for the target molecule, was expected to give an insight on the influence 
of the DNA binder on the eventual radiotoxic effects of the pyrazolyl-diamine 
99m
Tc(I) tricarbonyl 
complexes proposed in this thesis. 
1.6.2.3 Evaluation of DNA-binding 
The effect caused by DNA-binding units is dependent on the characteristics of the binding 
molecule and type of DNA, but also on the strength and mode of interaction. It can be measured 
by several techniques based on the chromophoric properties of the ligands, cytotoxic effects, 
structural changes on the DNA or thermodynamic properties of the interaction.  At macroscopic 
level it can be detectable trough inhibition of cell growh or cell transformation as a result of 
disturbance in the DNA dynamics. Some examples of physical/chemical methods that can 
estimate the mechanism and/or the occurrence of these interactions are: structural techniques 
(gel electrophoresis, X-ray crystallography); spectroscopic techniques (NMR, UV-Visible, 
fluorescence, circular and linear dichroism), viscosity measurements
56,57,59
; thermodynamic 
experiments (isothermal titration calorimetry)
56
 or computational molecular modeling
58
.  
This section will focus on the fluorescence and UV-Vis spectroscopy as these are the 
techniques that have been used in the studies reported in this thesis. These techniques are 
suitable to confirm the occurrence of interaction and for the determination of the binding 
constant (K) by titration methods. More detailed information about these techniques can be 
found elsewhere.
61
  A brief overview is presented below. 
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The UV-Vis absorption spectroscopy can be used to detect changes in the absorption 
properties of the ligand or the DNA when the interaction occurs. The DNA molecule presents a 
broad absorption band at 200-250 nm with a maximum at 260 nm in the UV region. The 
common studied DNA-binding molecules, in general, also present a characteristic absorption 
band in the UV-Vis absorption spectrum. The complex ligand-DNA presents a shift on the 
position of the maximum absorption, in both cases, relative to the free molecule in solution. 
Thus, the comparison of these spectra can be used to assess the ligand-DNA interaction. The 
magnitude of the shifting indicates the strength of the interaction and the presence of 
hypochromism and bathochromism (red shift) usually indicates intercalative mode of binding. 
Fluorescence spectroscopy is a very sensitive technique and very suitable for these studies as 
the DNA-binding drugs usually correspond to aromatic compounds that present high intensity 
fluorescence. The changes in environment, like the binding to the DNA molecule, can cause 
spectral shifts relative to the excitation and emission of the fluorescence of the ligands. The 
enhancement of the fluorescence intensity indicates interaction with the DNA, where higher 
enhancements are commonly observed for intercalative binding-mode while a decrease 
indicates groove-binding mode. 
1.6.3 Functionalization with a bioactive peptide and a nuclear 
localization sequence: a perspective 
The main purpose of the synthesis and evaluation of the AO- and anthracene-containing 
pyrazolyl-diamine 
99m
Tc(I) tricarbonyl complexes proposed in this thesis was to find 
organometallic building blocks that could reach the cell nucleus and target the DNA of any cell. 
If shown some ability to induce significant cell death, the next step would be the 
functionalization of these building blocks with a peptidic BM and a NLS for targeted cancer 
therapy.  
1.6.3.1 Bioactive peptide 
The identification and characterization of BMs, their molecular targets and mechanisms of 
action, allow advances in pharmacological applications based on drug delivery systems. This is 
a multidisciplinary area that involves organic chemistry, biochemistry and molecular biology 
focused on the isolation of the natural occurring BMs as well as its mimicking by synthetic 
congeners. There is a constant search for new BMs and its targets and some have been well 
characterized and successfully applied as biologically active targeting vectors.
68
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Bioactive peptides are part of the class of biomolecules that mediate the intercellular signalling 
process. This signalling occurs upon development and regulation of physiological processes in 
response to external conditions. The bioactive peptides are very specific and efficient 
messengers and require fewer resources from the cells compared to the proteins. They are 
synthesized then activated by post-translational modification and stored in secretory vesicles. 
When released they bind to their target (usually G-protein coupled receptors (GPCR)) that 
initiates the process of cellular response, which depends on the type of cell. The same cell can 
express and respond to a variety of different bioactive peptides from neighbour or distant cells. 
The receptors also present different subtypes that provide different response to the same 
peptide.
69
 
Bombesin (BBN) is an amphibian tetradecapeptide that binds to a GPCR which comprise four 
receptor subtypes (see Table 1.5). In this work, it was intended to functionalize the 
99m
Tc(I) 
tricarbonyl complexes with BBN analogues for the targeting of gastrin-releasing peptide (GRP) 
(subtype BB2) receptor that is overexpressed in several tumor cells, such as prostate, breast, 
pancreatic, and small-cell lung cancer cells.
70–73
 The well characterized bombesin peptide 
analogues can be used as tumor-seeking vectors for both diagnostic and (radio/chemo)-therapy 
of those tumors. In nuclear medicine, these BMs can be radiolabeled directly or through the use 
of a bi/multifunctional ligands, as seen in previous sections. An overview of radiolabeled BBN 
conjugates that seek GRP-receptor can be found in several reviews
72,74–77
.  
Table 1.5 Bombesin receptor subtypes and the respective native peptide sequences
77
 
 
1.6.3.2 Nuclear localization sequence 
All the translation process occurs outside the nucleus but some proteins that regulate important 
cell functions in eukaryotic cells are required by this organelle. The traffic of macromolecules 
into the nucleus is a controlled and restricted active transport, mediate by nuclear receptors and 
other proteins of the nuclear pore complex (NPC) as well as the GTPase Ran that generates 
energy. Small molecules can diffuse through the NPC by passive transport, but for 
macromolecules up to 45-50 kDa the required signal to translocate through the NPC is the NLS. 
The NLS is recognized by members of the cytosolic Importin/Karyopherin super family of 
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proteins which sets the beginning of the import process.
78–82
 This signal sequence is of great 
interest for nuclear delivery systems design and it has been explored in areas like gene therapy 
researches but with limited success. The delivery of peptidic drugs on the other hand presents 
more encouraging platforms.
80,81
 
Table 1.6 Exemples of nuclear localization sequences of the different classes
80,81
 
SV40 large T-antigen PKKKRKV  (classical monopartite) 
Nucleoplasmin KRPAATKKAGQA- KKKK (classical bipartite) 
hnRNPA1 (M9) NQSSNFGPMKGGNFGGRSSGPYGGGGQYEAKPRNQGGY (non-classical) 
Table 1.6 shows some examples of the most studied sequences of each of the different NLS’s 
classes. The main difference between the classical and non-classical NLSs is that the classical 
NLSs possess short stretch (s) of basic amino acids. Those stretches can be continuous 
(monopartite) or separated by a spacer (bipartite).
80,81
 
[31] 
 
2 Results and discussion: synthesis and characterization of the ligands and 
complexes 
2.1 Synthesis and characterization of the ligands 
Pyrazole-diamine ligands bearing anthracene or acridine orange as DNA-binding groups were 
synthesized in order to obtain stable 
99m
Tc compounds with the ability to intercalate the DNA 
and display enhanced radiotoxic effect through Auger electrons emission. The ligands were 
expected to position the radionuclide at different distances to the target by introduction of two 
different spacers between the chelator backbone and the DNA-binding moiety. 
As illustrated in Scheme 2.1, the synthesis of L1 was performed using a multistep synthetic 
strategy as reported in the literature, starting from the commercially available 9-anthracene 
aldehyde.
45
  
 
Scheme 2.1 Synthesis of Ant-CH2-pzNN  (L1) 
The multistep synthesis of L1 started with the reduction of 9-anthracene aldehyde with sodium 
borohydride in tetrahydrofuran (THF), which afforded 9-anthracenemethanol (1). The 
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bromination of the latter with liquid bromine (Br2) was carried out in dry acetonitrile (ACN) in 
presence of the reducing agent triphenylphosphine (PPh3) at 0°C. The resulting brominated 
derivative, compound 2, was then alkylated with acetylacetone in THF in presence of the base 
sodium hydride (NaH) to give 3 in keto form. Cyclisation of 3 with 2-hydroxyethyl hydrazine in a 
mixture of ethanol and chloroform (1:1) at 0°C afforded compound 4, which was brominated 
with phosphorus tribromide (PBr3) under reflux in toluene giving compound 5. L1 was obtained 
by treatment of 5 with an excess of 1,2-diaminoethane in methanol (MeOH) under reflux. L1 
was purified by silica-gel (SiO2) column chromatography, and obtained as a yellow oil in low to 
moderate yield (21%). The characterization of L1 was done by 
1
H-NMR spectroscopy and 
HPLC (see experimental section), and confirmed the formation of the desired anthracenyl-
containing chelator as checked by comparison with the spectroscopic data reported in the 
literature for L1.
45
 
The synthesis of Ant-(CH2)3-pzNN (L2) and AO-(CH2)3-pzNN (L3), which contain anthracenyl or 
acridine orange moieties and a longer propylenic linker to attach these DNA binding moieties to 
the chelator framework, was performed according to the literature. This was done using a 
similar strategy that involved the use of a common N-hydroxysuccinimine (NHS) activated ester 
pyrazole-diamine derivative, containing a terminal tert-butyloxycarbonyl (BOC)-protected amine 
group, which was coupled to 3-(anthracen-9-yl)propan-1-amine or 10-(3-aminopropyl)-3,6-
bis(dimethylamino)acridinium through their amine groups.
83
 The syntheses of the activated 
ester derivative, amine precursors of the DNA binding molecules and final chelators are 
described below. 
The N-hydroxysuccinimine (NHS) activated ester was synthesized as described previously, 
according to the reactions presented in Scheme 2.2.
84
 Its multistep synthesis started with the 
preparation of compound 6, undergoing a keto-enol equilibrium, which was obtained by C-
alkylation reaction between 2,4-pentanodione and ethyl bromoacetate in presence of NaH in 
THF at 0°C. The cyclocondensation of 6 with 2-hydroxiethylhydrazine in EtOH at 0°C originated 
7. The latter was brominated with PBr3 under reflux in toluene to give 8. Another method that 
has been used to obtain 8 was the bromination of 7 with tetrabromomethane (CBr4) in presence 
of PPh3 in THF. Compound 8 was N-alkylated with tert-butyl 2-aminoethylcarbamate (9) in 
presence of potassium carbonate (K2CO3) and potassium iodide (KI) in ACN to give compound 
10. Then, the protection of the secondary amine of 10 was carried out by treatment of this 
compound with Boc2O in THF at 0°C, which led to the formation of the BOC-protected derivative 
11. The alkaline hydrolysis of 11 with aqueous NaOH under reflux in THF originated 12 that was 
activated by NHS in presence of 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) in 
dichloromethane (DCM) at 0°C, yielding the desired activated ester 13. 
 
2. Synthesis and characterization of the ligands and complexes 
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Scheme 2.2 Synthesis of the N-hydroxysuccinimine (NHS) activated ester pyrazole-diamine derivative (13) 
The next step was the synthesis of already described amine precursors functionalized with the 
DNA binding molecules anthracene and acridine orange (AO). Both precursors were obtained 
by the methods reported in the literature.
83
 
The anthracene-containing precursor 3-(anthracen-9-yl)propan-1-amine (14) was obtained by 
hydrogenation of the commercially available 2-(anthracen-9-yl)acrylonitrile with lithium 
aluminum hydride (LiAlH4) in diethyl ether (Et2O) under reflux as shown in Scheme 2.3. 
 
Multifunctional Organometallic Compounds for Auger Therapy  
 
 
 
[34] 
 
 
Scheme 2.3 Synthesis of 3-(anthracen-9-yl)propan-1-amine (14) 
The synthesis of 10-(3-aminopropyl)-3,6-bis(dimethylamino)acridinium (18) was more 
demanding and involved several steps, as shown in Scheme 2.4.
83
 Briefly, compound 15 was 
obtained by alkylation of phthalimide with dibromopropane under reflux in acetonitrile. Then, its 
iodination with KI in acetone under reflux originated 16. The latter was reacted with commercial 
acridine orange to give 17. Removal of the phthalimide group with excess of hydrazine 
monohydrate in MeOH gave 18, which has been isolated in low yield. 
 
Scheme 2.4 Syntheis 10-(3-aminopropyl)-3,6-bis(dimethylamino)acridinium (18) 
As presented in Scheme 2.5, the conjugation of the activated ester 13 with compounds 14 and 
18 led to the synthesis of BOC-protected pyrazolyl-diamine derivatives, 19 and 20 respectively. 
These conjugation reactions were performed in presence of the base N,N-diisopropylethylamine 
(DIPEA) in dichloromethane (19) or dimethylformamide (20). The deprotection of the amine 
groups of 19 with an excess of trifluoroacetic acid (TFA) in DCM gave L2, which was isolated as 
a yellow solid. Compound 20 was deprotected with hydrochloric acid (HCl) in MeOH to give L3, 
2. Synthesis and characterization of the ligands and complexes 
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which was isolated as a dark red solid after purification by alumina (Al2O3) column 
chromatography.  
 
Scheme 2.5 Synthesis of Ant-(CH2)3-pzNN (L2) and AO-(CH2)3-pzNN (L3) 
 
L2 and L3 were characterized by 
1
H-NMR spectroscopy and by HPLC. Unlike L2, L3 was 
obtained with very low yield in very low amount (10 mg). For this reason, it was not further used 
to synthesize the corresponding 
99m
Tc(I) and Re(I) tricarbonyl complexes. The lack of available 
time also did not allow the possibility of repeating the synthesis of L3. 
If synthesized with success, the fourth ligand (L4) would be a new AO-containing chelator. Two 
strategies have been devised to synthesize L4. The first strategy that has been studied involved 
the direct coupling of a brominated BOC-protected pyrazole-diamine derivative with acridine 
orange, as proposed in Scheme 2.6. L4 would be obtained after deprotection of the amine 
groups. 
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Scheme 2.6 First strategy for the synthesis of AO-CH2-pzNN (L4) 
The second strategy was based on the prior functionalization of a tritylated pyrazole derivative 
with AO, followed by the building-up of the pyrazolyl-diamine backbone and removal of the trityl 
protecting group, as shown in Scheme 2.7. 
 
Scheme 2.7 Second strategy for the synthesis of AO-CH2-pzNN (L4) 
 
In the first strategy, two approaches were attempted to obtain the starting brominated BOC-
protected pyrazole-diamine derivative (Scheme 2.8). Both approaches involved the synthesis of 
compound 23 as a key intermediate. In one of these approaches, the central amine was 
protected with BOC before conversion of the alcohol function to a bromide, while in the other 
one such protection was not performed. 
The multistep synthesis of 23 started with the formation of a 2-hydroxyethylpyrazole derivative, 
compound 21, which was obtained as described in the literature, by cyclocondensation of ethyl 
2-formyl-3-oxopropanoate with 2-hydroxyethylhydrazine in EtOH at 0°C.
85
 The new compound 
ethyl 1-(2-bromoethyl)-1H-pyrazole-4-carboxylate (22) was obtained with a moderate-high yield 
of 66%, by bromination of 21 with CBr4 in presence of PPh3 in THF at 0°C. Then, 23 was 
obtained by treatment of 22 with excess of 9 in presence of K2CO3 and KI in dry ACN under 
reflux.  
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In the first approach, the reduction of the ester group of 23 with LiAlH4 in THF successfully 
afforded compound 24, which contains a hydroxymethyl group at the 4-position of the pyrazolyl 
ring and does not present the central amine group protected with BOC (Scheme 1.8). However, 
the bromination of the hydroxymethyl group of 24 with CBr4 in THF in presence of PPh3 did not 
afford the desired compound. Thus, a second approach involved the protection of the 
secondary amine of 23 with Boc2O in THF at 0°C. The resulting ethyl 1-(2-(tert-
butoxycarbonyl(2-(tert-butoxycarbonylamino)ethyl)amino)ethyl)-1H-pyrazole-4-carboxylate (25) 
was isolated with a very high yield of 99%. Reduction of 25 with LiAlH4 gave 1-(2-(tert-
butoxycarbonyl(2-(tert-butoxycarbonylamino)ethyl)amino)ethyl)-1H-pyrazol-4- hydroxymethyl 
(26), which was obtained as a yellow oil with moderate yield (54%). Likewise in the first 
approach, bromination of 26 with CBr4 in THF in presence of PPh3 also did not provide the 
desired brominated derivative. 
 
Scheme 2.8 Synthesis of tert-butyl 2-(2-(4-(hydroxymethyl)-1H-pyrazol-1-yl)ethylamino)ethylcarbamate 
(24) and 1-(2-(tert-butoxycarbonyl(2-(tert-butoxycarbonylamino)ethyl)amino)ethyl)-1H-pyrazol-4- 
hydroxymethyl (26)  
The new compounds involved in the attempted synthesis of L4 (see Scheme 2.8) were 
characterized by 
1
H and 
13
C-NMR spectroscopy, as exemplified for compounds 22, 25 and 26 in 
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Figure 2.1-Figure 2.4. The NMR characterization of all the compounds confirmed the proposed 
formulations and the presence of highly pure compounds. 
 
Figure 2.1 
1
H-NMR spectrum of ethyl 1-(2-bromoethyl)-1H-pyrazole-4-carboxylate (22) 
 
Figure 2.2 
13
C-NMR spectrum of ethyl 1-(2-bromoethyl)-1H-pyrazole-4-carboxylate (22) 
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Figure 2.3 
1
H-NMR spectrum of ethyl 1-(2-(tert-butoxycarbonyl(2-(tert-
butoxycarbonylamino)ethyl)amino)ethyl)-1H-pyrazole-4-carboxylate (25) 
 
 
Figure 2.4 
1
H-NMR spectrum of 1-(2-(tert-butoxycarbonyl(2-(tert-butoxycarbonylamino)ethyl)amino)ethyl)-
1H-pyrazol-4- hydroxymethyl (26) 
 
Finally, it has been explored the above mentioned second strategy to obtain L4. As presented in 
Scheme 2.9, this strategy involved the synthesis of 4-(bromomethyl)-1-trityl-1H-pyrazole (28). 
This involved the use of ethyl 1-trityl-1H-pyrazole-4-carboxylate, already described in the 
literature,
85
 as the starting material. This compound was converted to 27 by reduction of the 
ester group with LiAlH4 in THF at 0°C. 27 was brominated with PBr3 in toluene under reflux 
leading to 28. The coupling of 28 with commercial available acridine orange in xylene under 
reflux was not successful and did not lead to the desired AO-containing pyrazole derivative.  
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Scheme 2.9 Synthesis of 4-(bromomethyl)-1-trityl-1H-pyrazole (28) 
2.2 Synthesis and characterization of the Re(I) and 99mTc(I) tricarbonyl  
complexes 
To have an insight on the potential of the Auger emitter 
99m
Tc for the design of DNA-target 
radiotherapeutic agents, 
99m
Tc complexes containing a bifunctional chelator to stabilize the fac-
[
99m
Tc(CO)3]
+
 core and a DNA-binding moiety that ensure close proximity to the target, were 
synthesized. 
As seen in chapter 1, the Re congeners are used for characterization of the 
99m
Tc complexes by 
conventional analytical methods, which could not be possible for the very low concentration of 
the 
99m
Tc complexes that are produced from the [
99m
TcO4]
- 
obtained from the 
99
Mo/
99m
Tc 
generator. As seen before, only the ligands with the anthracenyl moieties, L1 and L2, could be 
successfully obtained in adequate amounts. Therefore, the synthesis of Re and 
99m
Tc 
complexes was uniquely performed for these two ligands. The respective complexes, Re1 and 
Re2, were obtained by reacting the corresponding ligands (L1 or L2) with the precursors 
[Re(CO)5Br] or [Re(H2O)3(CO)3]Br, respectively.
86
 
Re1 was synthesized as previously described, by an equimolar reaction of [Re(CO)5Br] with L1 
in MeOH under reflux (Scheme 2.10).
45
 After washing with hexane, Re1 was obtained as a 
yellow solid with a relatively high yield of 76% and characterized by 
1
H-NMR spectroscopy and 
HPLC (tR = 22.90 min). The characterization of Re1 provided 
1
H NMR data consistent with 
those reported in the literature for this complex, confirming the presence of a pyrazolyl-diamine 
ligand coordinated in a N,N,N-tridentate fashion to the fac-[Re(CO)3]
+
 core. 
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Scheme 2.10 Synthesis of Re-Ant-CH2-pzNN (Re1) by reaction of L1 with the precursor [Re(CO)5]Br 
Re2 was synthesized by reacting equimolar amounts of [Re(H2O)3(CO)3]Br with L2 in MeOH 
under reflux (Scheme 2.11), as previously described for similar compounds.
46
 The purification of 
Re2 was done by washing with Et2O and CHCl3. After purification, Re2 was obtained as a 
yellow solid in a moderate yield of 62%. Like Re1, Re2 is an air and water stable compound, 
with good solubility in aqueous solution but low solubility in common organic solvents such as 
CHCl3. The characterization of Re2 was performed by 
1
H and 
13
C-NMR spectroscopy, HPLC 
and ESI-MS.  
 
 
Scheme 2.11 Synthesis of Re-Ant-(CH2)3-pzNN (Re2) by reaction of L2 with the precursor 
[Re(H2O)3(CO)3]Br 
As shown in Figure 2.5, the ESI-MS spectrum of Re2 shows a prominent peak corresponding to 
the expected molecular ion ([M]
+
] at m/z = 728.5) with the correct isotopic distribution pattern.  
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Figure 2.5 ESI-MS spectrum of Re-Ant-(CH2)3-pzNN (Re2) 
The NMR characterization of Re2 confirmed the proposed formulation. The assignments of the 
different signals on the 
1
H and 
13
C-NMR spectra were done based on the 2D experiments 
COSY ([
1
H, 
1
H]) and HSQC ([
1
H, 
13
C]). The results of the experiments are presented below 
(Figure 2.6 to Figure 2.9).  
 
Figure 2.6 [
1
H, 
1
H] COSY spectra of Re2 in CD3OD (ampliation of the aliphatic region) 
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Figure 2.7 
1
H-NMR spectra of Re2 in CD3OD 
 
Figure 2.8 [
1
H, 
13
C] HSQC spectra of Re2 in CD3OD (ampliation of the aliphatic region) 
 
Figure 2.9 
13
C-NMR spectra of Re2 in CD3OD 
The 
99m
Tc congeners of complexes Re1 and Re2 were obtained by reacting the respective 
ligands with the precursor fac-[
99m
Tc(H2O)3(CO)3]
+
 in aqueous solution. The aqueous fac-
[
99m
Tc(H2O)3(CO)3]
+
 was synthesized using pertechnetate obtained from the 
99
Mo/
99m
Tc 
generator. Briefly, the Na[
99m
TcO4] solution was added to an Isolink kit and the mixture heated 
for 30 min at 100°C and pH = 11. The precursor (tR = 6-7 min) was obtained with high yield and 
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purity ( > 95 %) as can be verified in the HPLC chromatogram presented in Figure 2.10, with 
negligible or non-existing amount of unreacted [
99m
TcO4]
-
 (tR = 3-4 min). 
 
Figure 2.10 HPLC trace of the precursor [
99m
Tc(H2O)3(CO)3]
+ 
 
Scheme 2.12 Synthesis of Tc1 and Tc2 with the precursor  fac-[
99m
Tc(H2O)3(CO)3]
+
 
As shown in Scheme 2.12, L1 and L2 were reacted with an aqueous solution of the tricarbonyl 
precursor to give Tc1 and Tc2. Ethanolic solutions of the ligands were added to an aqueous 
solution of the precursor at pH = 7.4. The resulting mixtures, having 10
-4
 or 10
-3
 M 
concentrations of L1 and L2, were heated for 30 min at 80°C and 100°C, respectively. The 
synthesized complexes, Tc1 and Tc2, were analyzed by HPLC and their retention times 
compared with those of the Re congeners (Figure 2.11 and Figure 2.12).  
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Figure 2.11 HPLC chromatograms of Tc1 and Re1 obtained by γ- and UV-detection, respectively 
 
Figure 2.12 HPLC chromatograms of Tc2 and Re2 obtained by γ- and UV-detection, respectively 
The HPLC analysis confirmed that Tc1 and Tc2 were obtained in high radiochemical purity. 
Moreover, the retention times of Tc1 and Tc2 are almost superimposed with those of Re1 and 
Re2, respectively (see Figure 2.11 and Figure 2.12), showing that we are in the presence of 
isostructural complexes. The small difference in retention time between the 
99m
Tc complexes 
and respective Re counterparts is due to the flow of the analyte in the HPLC system which 
passes through the UV detector first, and then through the gamma detector. 
Both 
99m
Tc complexes, Tc1 and Tc2, were purified by HPLC before further in vitro and biological 
studies presented in the next chapter. The analytical control revealed high purity of the purified 
complexes. 
 
[47] 
 
3 Results and discussion: in vitro and biological studies 
3.1 Spectroscopic studies of the interaction of the ligands and 
corresponding Re(I) complexes with the DNA molecule 
The interaction of the ligands and Re complexes with the DNA was evaluated by UV-Vis and 
fluorescence spectroscopic studies with CT-DNA. The use of these techniques for DNA-binding 
studies has been reviewed in Section 1.6.2.3.  
Spectroscopic studies (UV-Vis, Fluorescence, Linear and Circular Dichromism) of interaction of 
L1 and Re1 with the DNA have been described in the literature.
45
 
The spectra of the L2 and Re2 were obtained for different CT-DNA/probe ratios. The CT-DNA 
was added to the probes until no change was observed in the spectra, meaning that all the 
probes were bounded to the DNA molecule. The comparison is done with the spectra of the free 
probe in solution. All the measurements were carried in phosphate buffer saline (PBS) (10 mM, 
pH = 7.2). 
 
Figure 3.1 Absorption spectra of solutions containing 50 µM of L2 (left) or 100 µM of Re2 (right) in PBS 
(10 mM, pH = 7.2) with different equivalent amounts of CT-DNA. 
By analyzing the obtained spectra shown in Figure 3.1, slight hypochroism and red shifting can 
be observed on the bands of the anthracenyl chromophores upon addition of CT-DNA for both 
L2 and Re2. A negligible broadening on the vibronic strcture of the anthracene absorption 
bands can be noticed. No isosbestic points, which are indicator of the conversion of free probes 
to the bound ones, could be observed, in any of the cases.  
The intrinsic binding constants (K) were estimated by Scatchard model through UV-vis 
spectra.
45,67
 The K was determined from the plot of D/Δεap vs D, where D is the concentration of 
DNA in base pairs and Δεap = [εB - εF]. εap is the apparent extinction coefficient and it can be 
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calculated as the ratio of the observed absorbance of the sample and the total concentration of 
the probe (Aobs/[probe]). εB and εF are the extinction coefficients of the bound and the free forms 
of the probe, respectively.  
The absorption data were fitted to the following equation:  
D / Δεap = D / Δε + 1 / D/ΔεK 
Where Δε = [εB - εF] εB was confirmed through an independent method, in which the absorbance 
was extrapolated from a linear plot of the absorbance vs 1/[DNA] for [DNA] >>[probe]. 
Table 3.1 Intrinsic binding constants (k) of L1, Re1, L2 and Re2 
K [M
-1
] 
L1* (1.06 ± 0.01) x 10
4
 
Re1* (1.95 ± 0.01) x 10
4
 
L2 8.37 x 10
2
 ± 1.32 x 10
-6
 
Re2 2.20 x 10
3
 ± 1.0 x 10
-6
 
*Data from the literature45,87 
In general all the compounds present low to moderate affinity for the DNA molecule, but with the 
obtained results alone it is not possible to determine the type of interaction. By analysis of the 
values presented in Table 3.1, we can consider that L1 and Re1 have higher affinity for DNA 
than L2 and Re2, as they present higher K values. In both cases the Re complexes present 
higher affinity than the respective ligands most likely due to their intrinsic cationic character. 
 
Figure 3.2 Fluorescence spectra of solutions containing 8 µM of L2 (left) or Re2 (right) in PBS (10 mM, 
pH = 7.2) with different equivalent amounts of CT-DNA 
A decrease in fluorescence intensity upon addition of increasing amounts of CT-DNA can be 
observed for both compounds, but more significant for Re2 than for L2 (Figure 3.2). This 
quenching in the fluorescence indicates interaction with the DNA molecule as usually observed 
for anthracenyl chromophores.
67
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The Stern-Volmer constant (Ksv) could be estimated for L2 and Re2 based on the respective 
fluorescence spectra obtained in the presence of DNA.
67,88
 This parameter measures the 
efficiency of quenching by DNA and can be obtained using the following equation:  
Io / I = 1 + Ksv [DNA] 
where Io and I are the fluorescence intensities in the absence and in the presence of DNA. 
Table 3.2 Stern-Volmer constant (Ksv) of L2 and Re2 
Ksv [M
-1
] 
L2 (1.55 ± 0.09) x 10
3
 
Re2 (5.56 ± 0.42) x 10
3
 
By the linearity of the obtained plots (Figure 3.2) and the Ksv values presented in Table 3.2, 
moderate affinity of both ligand and Re complex for the DNA can be considered. Once again 
Re2 seems to present higher affinity for the DNA as indicated by the higher Ksv. 
3.2 Lipophilicity of the 99mTc complexes 
Biodistribution and efficient delivery of therapeutic drugs can be limiting for its clinical 
application. To estimate the capability of the drug to cross biological barriers and/or interact with 
biological entities such as receptors, transporters or other macromolecules, several physical-
chemical properties can be evaluated, where the lipophilicity is of major interest. The lipophilicity 
can be measured by the partition coefficient (log P) in a two-phase system of two immiscible 
liquids, usually water and n-octanol (log Po/w). 
89,90
   
It is assumed that drugs can be separated into three categories according to the log Po/w values:  
low lipophilicity, log Po/w  ≤ 1.5; moderate lipophilicity, 1.5 ≤ log Po/w ≤ 4; and high lipophilicity, log 
Po/w ≥ 4.
91
 Table 3.3 presents the log Po/w values of the synthesized 
99m
Tc complexes, 
determined by the classical shaken-flask method which is adequate for moderately lipophilic 
compounds.
89
 
Table 3.3 Partition coefficient (log Po/w) values of Tc1 and Tc2 
Log Po/w 
Tc1* 1.41 ± 0.01 
Tc2 2.62 ± 0.19 
*Data from the literature48 
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Both complexes present moderate lipophilicity.
91,92
 Tc2 presents higher log Po/w value and, thus, 
it is more lipophilic than Tc1. This can be attributed to the presence of the additional propylenic 
linker introduced as a spacer between the anthracenyl and the pyrazolyl unit. 
3.3 In vitro stability and protein binding of the 99mTc complexes 
Stability studies in presence of natural chelators that present affinity for the fac-[
99m
Tc(CO)3]
+
 
core, such as amino acids and proteins that are very abundant in tissues and body circulation, 
are very important to predict reoxidation and transchelation reactions with the potential 
radiopharmaceuticals.  
Previously, it has been shown that Tc1 presents a good stability under  physiological conditions 
and in presence of natural chelators such as cysteine and histidine.
87
 Herein we tested also the 
ability of the complex Tc2 to resist in the presence of human serum and in presence of an 
excess of the amino acid histidine, at physiological temperature and pH. For this purpose, 
solutions of Tc2 were incubated with a solution of histidine in PBS (pH = 7) for 2 hours and with 
human serum for 6 hours, both at 37°C. The solutions were analyzed by HPLC and the 
obtained chromatograms were compared with the HPLC chromatographic profile of Tc2 (Figure 
3.3 and Figure 3.4). 
 
Figure 3.3 Stability of Tc2 in presence of histidine in PBS (pH = 7)  after 2 hours of incubation at 37°C 
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Figure 3.4 Stability of Tc2 in presence human serum after 6 hours of incubation at 37°C 
Tc2 is stable in presence of histidine for at least 2 hours. No transchelation or other degradation 
was observed by analyzing the chromatographic profile of the incubated solution, which 
remained unchanged compared to the free Tc2 in solution as shown in Figure 3.3. 
Tc2 is also stable in the presence of human serum for at least 6 hours, as seen by analysis of 
the chromatograms presented in Figure 3.4. This assay was also used to estimate the binding 
of Tc2 with serum protein. To determine the percentage of protein binding of Tc2, the proteins 
were precipitated with ethanol and centrifuged. The activity of the precipitate (proteins) and 
supernatant were measured. It has been found that Tc2 shows a protein binding of 26 %, after 
6 h of incubation at 37 º C, which can be considered a low to moderate value. 
3.4 Cellular uptake and subcellular distribution of the 99mTc complexes  
As seen in previous section, the physical-chemical properties of the complexes, such as its 
lipophilicity, are very important to determine its ability to diffuse through the cell membrane 
without the need of active transport mechanisms. On the other hand, the polar and hydrophobic 
interactions with the constituents of the cell membrane such as lipids and proteins can dictate 
whether the complex will enter the cell or stay bounded to the membrane surface by 
intermolecular forces.
90
 It has been studied the cell uptake of Tc1 and Tc2 in murine and 
human tumor cells, as well as their subcellular distribution (nuclear and mitochondria uptake). In 
particular, the nuclear uptake is a crucial factor that was expected to strongly influence the 
potential radiotoxicity of the complexes, which is also reported below. 
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3.4.1 Cell uptake and cell internalization 
The studies were performed using the purified 
99m
Tc complexes, Tc1 and Tc2, using B16-F1 
murine melanoma and PC-3 human prostate cancer cells. The assays were performed after 
incubation of each compound with the desired cell line at 37°C, in the presence of cell medium, 
for different intervals of time (5 min-4h). After incubation, the non-bounded compounds were 
washed away so the cell uptake could be determined. These experiments were used to 
determine the total cell uptake, which corresponds to the total amount of 
99m
Tc complex 
internalized or bounded to the surface membrane of the cells. The same assays were also used 
to determine the cell internalized and membrane bound fractions, as described in detail in the 
experimental section. 
As seen in Figure 3.5, the cell internalization of the complex Tc1 is not significantly different for 
the two cell lines with a total internalization of about 17% for B16-F1 and 18% for PC-3 cells, 
after 4h incubation, which is about 55% of the total cell uptake in both cases. This means that 
about half of the total 
99m
Tc complex uptake by the cells is able to diffuse through the cell 
membrane, while 45% is retained at the membrane surface. Similar results were obtained for 
the complex Tc2 in both cell lines (Figure 3.6), i.e. 50% of the total 
99m
Tc complex is internalized 
by the cells after 4h incubation. However, the amount of internalized complex is about 5% for 
Tc2 in both cell lines, which is significantly lower that the values observed for Tc1. A 
comparison of the total cell uptake of Tc1 and Tc2 in the two cell lines is also shown in Figure 
3.7. 
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Figure 3.5 Cell internalization of Tc1 in function of time, after 4 hours incubation at 37°C, in B16-F1 cells 
(left) and PC-3 cells (right) 
 
Figure 3.6 Cell internalization of Tc2 in function of time, after 4 hours incubation at 37°C, in B16-F1 cells 
(left) and PC-3 cells (right) 
. 
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Figure 3.7 Cell uptake of Tc1 and Tc2 as a function of time, after 4 hours incubation at 37°C, in B16-F1 
and PC-3 cells 
In summary, a rapid time-dependent uptake is observed for Tc1 and Tc2, as can be seen in 
Figure 3.7. However, after 4 of incubation, Tc1 presents significantly higher uptake, about 35% 
in PC-3 cells and 30% in B16-F1 cells, if compared with Tc2 that shows an uptake of ca. 10% in 
both cell lines. These results are not consistent with the lipophilicity of the complexes 
determined in section 3.2, as Tc2 presented higher log Po/w than Tc1 (log Po/w = 1.41 for Tc1 
and 2.62 for Tc2) thus being more lipophilic. It is important to mention that there are several 
factors that influence the ability of the compounds to diffuse through biological membranes or to 
interact with its components other than lipophilicity, such as for example charge, size and 
topology of the molecules. Eventually, the lower molecular weight of Tc1 can justify its 
enhanced cellular uptake in comparison with Tc2. 
3.4.2 Nuclear and mitochondrial uptake 
The evaluation of the ability of the synthesized 
99m
Tc compounds to reach the nucleus and 
ensure closer proximity to the DNA is of major interest to determine its potential as therapeutic 
agents as seen in chapter 1. We also decided to evaluate if the compounds were able to 
accumulate in other organelles such as mitochondria by its isolation using the commercial kit 
Mitochondria Isolation Kit for Cultured Cells. This organelle is key for oxidative metabolism and 
apoptosis in eukaryotes. Studies have shown that several changes occur in structure and 
function of mitochondria of the cancer cells, making these organelles important targets for 
cancer diagnosis and therapy.
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The nuclear and mitochondrial uptakes of the 
99m
Tc complexes in function of total cell uptake 
were evaluated on B16-F1 and PC-3 cells and the results are presented below. The results 
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were obtained after 2 hours incubation at 37°C of the purified 
99m
Tc complexes with the cells, 
and are expressed in percentage of the total added activity. 
Table 3.4 Cellular, nuclear and mitochondrial uptakes of Tc1 in B16-F1 and PC-3 cells after 2 hours 
incubation at 37°C 
% Uptake/total activity (Tc1) B16-F1 PC-3 
      
Cell 30.0 (2.50)* 19.5 (2.30) 
Nucleus 23.6 (2.00) 15.6 (1.80) 
Mitochondria 0.9 (0.07) 0.2 (0.03) 
*The numbers in brackets represent the %uptake/total activity per million cells 
The nucleus uptake of Tc1 is about 80% of the total cellular uptake in both cell lines, while the 
mitochondrial uptake represents only about 3% of the total uptake for B16-F1 and 1% for PC-3 
cells (Table 3.4) after 2 hours. These results indicate that the majority of the internalized 
99m
Tc 
complex is able to reach the cell nucleus. 
Table 3.5 Cellular, nuclear and mitochondrial uptakes of Tc2 by B16-F1 and PC-3 cells after 2 hours 
incubation at 37°C 
% Uptake/total activity (Tc2) B16-F1 PC-3 
      
Cell 12.9 (1.00)* 8.8 (1.30) 
Nucleus 10.8 (0.80) 6.6 (0.90) 
Mitochondria 0.2 (0.01) 0.4 (0.06) 
*The numbers in brackets represent the %uptake/total activity per million cells 
Tc2 presents similar results at the same time point, with a nuclear uptake that corresponds to 
ca. 90% and 75% of the total cellular uptake in B16-F1 and PC-3 cells, respectively, while the 
mitochondrial uptake is minimal corresponding only to about 2% and 5% of the total uptake in 
B16-F1 and PC-3 cells, respectively (Table 3.5).  
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Figure 3.8 Cellular, nuclear and mitochondrial uptakes of Tc1 and Tc2 by B16-F1 and PC-3 cells per 
million cells after 2 hours incubation at 37°C 
In summary, there is a minimal accumulation of the complexes in the mitochondria but 
extremely high uptake by the nucleus in B16-F1 and PC-3 cells, after 2 hour incubation (Figure 
3.8). Tc1 presents higher nuclear targeting than Tc2, which certainly reflects its higher cell 
uptake.  
3.5 Cytotoxicity of the tricarbonyl complexes and respective ligands  
The cytotoxicity of the ligands and corresponding Re and 
99m
Tc complexes was evaluated by 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay on B16-F1 and PC-3 
cells. 
The MTT assay is a good indicator of cell viability by measurement of mitochondria activity.
94
 In 
normal cells the mitochondria enzymes are able to provide the conversion of tetrazolium salt 
MTT into formazan crystals, whose concentration can be determined by the lecture of 
absorbance at 540 and 720 nm in solution. A decrease in formazan crystals production reflects 
a decrease in mitochondria activity, and thus in cell viability.  
Usually the cytotoxicity of the drugs at different concentrations is determined by comparison 
with the controls (non-exposed cells). For rapid dividing cells, such as cancer cells, 50% 
inhibitory concentration (IC50) can be calculated which corresponds to the compound 
concentration inhibiting cell growth by 50%.  
3. In vitro and biological studies 
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3.5.1 Cytotoxicity of the ligands and Re complexes 
The cytotoxicity of the ligands (L1 and L2) and Re complexes (Re1 and Re2) was evaluated to 
estimate whether the chemical nature of the congener 
99m
Tc complexes would also contribute 
for cell toxicity in the range of concentrations (10
-7
-10
-9
 M) involved in the synthesis of non-
carrier added 
99m
Tc complexes.  
The cells were incubated with solutions of the tested compounds at increasing concentrations at 
37°C for 40 hours. The cell viability was assessed by the MTT assay and compared with that of 
controls, i.e. cells not exposed to the compounds. The results obtained are presented in Figure 
3.9 and Figure 3.10.  
For concentrations lower than 5 µM and 10 µM, respectively, L1 and Re1 can be considered 
non-toxic for B16-F1 cells, as seen in Figure 3.9 (left). At higher concentrations there is a 
significant inhibition in cell growth with reduced cell survival of almost 0%. For PC-3 cells, 
cytotoxic effects are observed only at concentrations higher than 10 µM and 20 µM for L1 and 
Re1, respectively (Figure 3.9 (right)). For L2 and Re2, the cytotoxic effects are observed at 
concentrations higher than 20 µM and 50 µM for B16-F1 cells and 50 µM and 100 µM for PC-3 
cells, respectively (see Figure 3.10).  
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Figure 3.9 Cytotoxicity of L1 and Re1 at different concentrations, after 40 hours incubation at 37°C, in B16-
F1 cells (left) and PC-3 cells (right) 
 
Figure 3.10 Cytotoxicity of L2 and Re2 at different concentrations, after 40 hours incubation at 37°C, in 
B16-F1 cells (left) and PC-3 cells (right) 
Table 3.6 50% inhibitory concentration (IC50) of L1, Re1, L2 and Re2 in B16-F1 and PC-3 cells 
IC50 [µM] 40h B16-F1 PC3 
   
L1 8.1 ± 4.1 28.9 ± 16 
Re1 31.3 ± 16.9 46.6 ± 14 
L2 56.6 ± 31.8 119.8 ± 80 
Re2 153.0 ± 110.0 377 ± 307 
The cytotoxicity assays allowed the determination of IC50 values (Table 3.6). In both cases, the 
ligands are more cytotoxic than the Re complexes as lower concentration is needed to reduce 
cell growth by 50%. This could be due to the facility of the compounds to enter the cells, which 
is dependent on their structural characteristics, showing that the presence of the metal 
influences the ability of the ligands to interact with biological systems. The results also indicate 
that B16-F1 cells are more susceptible to the toxic effects of the ligands and Re complexes than 
PC-3 cells. 
3. In vitro and biological studies 
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L1 and Re1 show significantly higher cytotoxic effects than L2 and Re2 respectively, which is 
consistent with the cell uptake and internalization studies with the corresponding 
99m
Tc 
complexes. It is possible that, similarly to the corresponding 
99m
Tc complexes, L1 and Re1 have 
enhanced ability to enter the cells and accumulate into the nucleus, leading to higher cytotoxic 
effect via disturbance in the structure and dynamics of the DNA molecule. This possibility is 
more plausible for the isoestrutural Re congeners, as the substitution of 
99m
Tc for this metal 
wouldn’t change significantly the intrinsic properties of the final organometallic complex. 
Nevertheless, this discussion has to be done with caution since the standard deviation values of 
the measured IC50 values are rather high. 
3.5.2 Radio-cytotoxicity of the 99mTc complexes 
Once the synthesized 
99m
Tc complexes were able to enter the cells and reach the nucleus, their 
radio-cytotoxicity was evaluated in the same cell lines. Moreover, the cytotoxicity studies with 
the ligands and Re congeners also showed that at concentrations lower than 10
-6
 M the non-
radioactive congeners are not cytotoxic. Therefore any toxic effect presented by the 
99m
Tc 
complexes will be due to the radioactive decay of the 
99m
Tc radionuclide, as the excess of free 
ligands has been separated by HPLC. 
The cells were incubated with solutions of the
 99m
Tc tricarbonyl complexes (Tc1 and Tc2) with 
increasing activities, at 37°C for 40 hours. The radio-cytotoxicity of the complexes was then 
determined by MTT assay. The viability of the cells was compared to that observed in controls 
and the inhibitions of cell growth were calculated in percentage.  
Solutions of the non-nucleus/DNA targeting pertechnetate were also used as controls at the 
highest activities used for the 
99m
Tc complexes and as expected, did not show radio-cytotoxic 
effects in any of the cases. 
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Figure 3.11 Radio-cytotoxicity of Tc1 at different activities, after 40 hours incubation at 37°C, in B16-F1 
cells (left) and PC-3 cells (right) 
The complex Tc1 did not show any radio-cytotoxic effect in the range of the studied activities 
(0.2-50 µCi/9 x 10
3
 cells per 200 µL of culture medium), which are considered relatively high, 
with almost 100% of cell survival in both B16-F1 and PC-3 cell lines after 40 hours (Figure 
3.11). These results are very different from the ones obtained in the previous studies where the 
same compound showed great radio-cytotoxic effect towards B16-F1 cells even, at low 
activities, with about 100% inhibition of cell growth after 2 hours incubation.
48
 These previous 
results can be attributed to matrix effect in the medium, as studies with related compounds 
show much less or no radio-cytotoxic effect even though these compounds were as efficient to 
enter the cells and target the nucleus.
46,48
 
 
Figure 3.12 Radio-cytotoxicity of Tc2 at different activities, after 40 hours incubation at 37°C, in B16-F1 
cells (left) and PC-3 cells (right) 
As seen in Figure 3.12, Tc2 also has no radio-cytotoxic effect in the range of the studied 
activities (0.2-50 µCi/9 x 10
3
 cells per 200 µL of culture medium), with almost 100% of cell 
survival in both B16-F1 and PC-3 cell lines after 40 hours. 
[61] 
 
4 Conclusions and future prospects 
This work falls within the ongoing research at CR group in the design and evaluation of 
multifunctional radioactive
 99m
Tc(I) organometallic compounds with the ability to target tumor 
cells and reach the nucleus for enhanced radiotoxic effects, due to Auger electron emission. A 
more specific goal of this thesis was to assess the influence of different structural factors that 
might determine the efficiency of cell internalization, nuclear targeting and radio-cytotoxic 
effects, such as the DNA-binding nature and the distance between the radionuclide and the 
target. The synthesis and evaluation of four 
99m
Tc complexes stabilized by pyrazole diamine 
ligands, bearing anthracene (L1 and L2) or acridine orange (L3 and L4) as DNA-binding units, 
were envisaged to elucidate the influence of those structural factors.  
The synthesis of the ligands was demanding with moderate to low yields. L1 and L2 were 
successfully obtained and the respective Re and 
99m
Tc complexes (Re1, Tc1, Re2, and Tc2) 
were synthesized and characterized. After several tries, L3 was finally obtained but in very low 
amount and could not be used for further studies. Two novel strategies to synthesize L4 were 
tried without success, so this ligand could not be obtained.  
Like Tc1/Re1, Tc2/Re were obtained with high yield and chemical/radiochemical purity. In the 
same way as Tc1, Tc2 has shown a high stability towards challenge reactions with the natural 
chelator histidine and in the presence of human serum. 
Both Tc1 and Tc2 showed the ability to enter into B16-F1 murine melanoma cells and PC-3 
human prostate cancer cell with significant high accumulation of the total internalized activity in 
the nucleus. Despite being more lipophilic, Tc2 present significantly lower uptake by both cell 
lines than Tc1, and thus lower accumulation in the nucleus.   
Although fluorescence and UV-Vis spectroscopic studies with the Re congeners showed that 
the complexes were also able to interact with CT-DNA, no cytotoxic effects of the 
99m
Tc 
complexes (Tc1 and Tc2) were observed at activities up to 50 µCi per 10
3
 cells in B16-F1 and 
PC-3 cells after 40 hours of incubation. These results contrast with ones reported previously in 
the literature for Tc1, which showed high radio-cytotoxic effect towards B16-F1 cells with almost 
100% of cell death in 24 hours. We attribute these conflicting results to matrix effects that might 
occurred in the previous studies. 
The obtained results indicate that the spacer influences the physical-chemical properties of the 
complexes, and thus its ability to penetrate through biological barriers. In this case, the longer 
spacer led to lower cell and nuclear uptake. As none of the complexes was able to cause 
cytotoxic effects, it was not possible to conclude whether the spacer could also affects the cell 
killing ability of the synthesized complexes by positioning the radionuclide at different distances 
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to the DNA. For the same reason we did not proceed with the functionalization of the 
synthesized complexes with a bioactive peptide and a NLS to enhance its potential as a 
targeted therapeutic agent. As the AO-containing 
99m
Tc complexes, Tc3 and Tc4, could not be 
synthesized we were not able to test the effect of the DNA-binding group either. 
From our results we conclude that an efficient delivery system of 
99m
Tc at single cell level could 
be provided but the radionuclide did not exert enhanced radiotoxic effects. In other words, the 
synthesized compounds were able to provide delivery of 
99m
Tc to its target but the Auger 
electrons emission did not display sufficient energy for significant cell killing.  
The use of Auger emitters for target radionuclide therapy is a very complex issue. In the 
particular case of 
99m
Tc complexes, several questions remain to be addressed: i) influence of 
DNA-binding mode in DNA damage and radiotoxicity; ii) role of direct or indirect effects in DNA 
damage and cell killing ability if compared with other Auger emitters; iii) relashionship between 
DNA damage, generation of ROS species and cell death outcome; iv) minimum threshold of 
accumulated radioactivity per cell nucleus to obtain significant radiotoxic effects, etc. 
Our complexes did not show any radio-cytotoxic activity for the tested radioactivity values, but 
we consider that it is worthwhile to evaluate their ability of inducing DNA damage using naked 
DNA (e.g. plasmid DNA) and using single-cell gel electrophoresis experiments (e.g comet 
assay), while assessing also the formation of ROS both in vitro (plasmid DNA) and in vivo 
(tumor cell lines). By extending such studies to the initially proposed AO-containing congeners, 
which are being synthesized by other students at the RS Group, we expect to address some of 
the above mentioned questions. Thus, we anticipate that our research will have a better ability 
of contributing to clarify whether 
99m
Tc has relevance for targeted Auger Therapy, which remains 
an unanswered scientific question.   
[63] 
 
5 Experimental section  
5.1 General aspects 
The manipulation of chemical compounds was performed according to good laboratory practice. 
Protective lead barriers were used in the manipulation of all the radioactive compounds. The 
control of the radiation dose absorbed by the handler was performed by reading individual 
dosimeters.  
 All the chemical reactions were performed at room temperature except when indicated. In 
those cases, ice bath was used to lower the temperature to 0ºC and dry or water bath was used 
to rise to the required temperature.  
Compounds sensitive to air or humidity were treated with distilled and dry solvents and were 
handled under nitrogen (N2) atmosphere using Schlenk line techniques. The work-ups were 
performed under air.  
5.2 Materials and methods 
5.2.1 Solvents and reagents 
All chemical and solvents were of analytical grade (Sigma-Aldrich) and were used without 
further purification unless stated otherwise. 
Dry solvents used were distilled and dried according to the literature procedures then kept 
under nitrogen atmosphere and molecular sieves.
95
  
The compounds ethyl 1-trityl-1H-pyrazole-4-carboxylate, 2-(anthracen-9-yl)acrylonitrile; and the 
rhenium precursors fac-[Re(H2O)3(CO)3]Br and fac-[Re(CO)5Br] were prepared as described in 
the literature.
85,86
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5.2.2 Techniques for purification and/or characterization  
Nuclear Magnetic Resonance Spectrometry (NMR) 
1
H and 
13
C  NMR  spectra  were  recorded  on  a Bruker Avance 400 MHz   or 300  MHz 
spectrometers (IST, Lisbon, Portugal); the  chemical  shifts  are given in ppm and 
were referenced to the residual solvent resonances relative to tetramethylsilane (SiMe4). For 
complex Re2, the assignment of the 
1
H and 
13
C NMR resonances was done based on COSY 
and HSQC techniques.   
Mass Spectrometry (MS) 
Mass spectra were obtained on a spectrometer ESI/QITMS Bruker HCT with electrospray 
ionization by Dr. Célia Fernandes (CR Group, C
2
TN). The samples were prepared in MeOH. 
Thin Layer Chromatography (TLC) 
TLC was used to monitor chemical reactions and analyze the products obtained.  
Silica-gel (SiO2) plates (0.20 mm 60 Å-UV254, ALUGRAM® aluminum sheets from Macherey-
Nagel) were used to run the chromatograms, with exception of the acridine orange derivatives 
that were analyzed using aluminum oxide (Al2O3) matrices (0.25 mm 60 Å, glass support from 
Sigma-Aldrich); the chromatograms were revealed by  UV radiation (254 nm) or and/or using I2 
chambers.  
Column Chromatography 
This technique was used to purify some of synthesized compounds with  silica gel (60 Å 
with granulometry of 70 - 230 mesh ASTM (Merck)) or aluminum oxide (Sigma-Aldrich) as 
chromatographic supports. These supports were prepared with the appropriate solvent/eluent 
(s) and filled into glass columns with the proper dimensions. The choice of the eluents 
depended on the characteristics of the compounds to separate, and the column glass size on 
the amount used for the purification. The compounds were applied on the top of the column and 
eluted through gravity effect, and then collected as several small fractions. Those fractions were 
analyzed by TLC and separated in different sets according to the respective retardation factor 
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(Rf). The purified compounds were dried under reduced pressure and characterized by common 
analytical techniques.  
High Performance Liquid Chromatography (HPLC) 
HPLC was used to characterize and purify the 
99m
Tc compounds. It was also used to 
characterize the respective Re congeners and ligands. These studies were performed on a 
HPLC system constituted by a Perkin-Elmer LC 200 pump with an UV-Vis detector (Perkin-
Elmer LC 290) and a radiation detector (Berthold-LB 507A). The solvents were of HPLC grade 
and were purged with helium. The water was bidistilled from a quartz distillation unit and filtered 
by Millipore (0.22 µm) filters. The different methods used in the HPLC separations described in 
this thesis are presented below.  
HPLC conditions 
Analytical control of the ligands and Re complexes 
UV detection:  λ = 254 nm 
Column A: Macherey-Nagel EC 250/4 Nucleosil 100-10 C18 
Flow: 1 mL/min 
Eluents: A- 0.1% aqueous TFA; B- MeOH 
Method A 
 
Purification and/or analytical control of solutions containing 
99m
Tc compounds  
Radiation detection: γ radiation  
Step Time (min) % A % B Curve 
0 5.0 100 0 - 
1 3.0 100 0 1 
2 0.1 75 25 - 
3 5.9 75 25 - 
4 0.1 66 34 1 
5 10.9 0 100 - 
6 5.0 0 100 - 
7 0.1 100 0 1 
8 4.9 100 0 - 
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Column B: Macherey-Nagel EC 250/3 Nucleosil 100-5 C18  
Flow: 0.5 mL/min 
Eluents: A- 0.1% aqueous TFA; B- ACN 
Method B 
 
*In some cases, the running time of this step was reduced as it does not affect the retention time and 
separation of the compounds 
Purification of 
99m
Tc complexes 
When needed, the purification of the 
99m
Tc complexes consisted on applying a higher amount 
(0.5-1 mL) of the sample into the HPLC system, and the run performed using the same 
conditions as for the analytical control of the complexes. The fractions corresponding to the 
desired complexes were collected in falcon tubes containing a small amount of phosphate 
buffered saline (PBS) 0.1 M (pH=7) (100 µL). Then, the eluent (ACN) was evaporated under N2.  
The purity of the collected complexes was checked by analytical HPLC using the same elution 
conditions.  
Activity measurements of radioactive solutions 
The  activity  of  the radioactive  solutions  was  measured  in  an  ionization  chamber  (Aloka,  
Curiemeter IGC-3). The samples with lower activity (less than 2 µCi) were measured in a 
Gamma counter (Berthold, LB2111).  
Step Time (min) % A % B Curve 
0 5.0 100 0 - 
1 0.3 100 0 - 
2 0.1 75 25 1 
3 5.9 75 25 - 
4 0.1 66 34 1 
5 8.9 0 100 - 
6 17.0 (7.0)* 0 100 - 
7 0.1 100 0 1 
8 4.9 100 0 - 
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5.3 Synthesis and characterization of the ligands 
5.3.1 Synthesis and characterization of the pyrazol units  
(Z)-ethyl 3-acetyl-4-hydroxypent-3-enoate (6) 
 
2,4-pentanodione (1.50 mL, 14.58 mmol) was added, drop wise, to a suspension of NaH (0.65 
g, 27.09 mmol) in dry THF (20 mL) at 0ºC. The mixture was stirred for 1 h followed by slow 
addition of ethyl bromoacetate (1.60 mL, 14.49 mmol) at the same temperature. The stirring 
mixture was left overnight at room temperature. HCl 2M was added at 0ºC and the compound 
was extracted with Et2O. The organic phase was then separated, dried with MgSO4 and filtered. 
The solvent was evaporated under reduced pressure and the product dried under vacuum.  
Yield: 82% (2.23 g) of a yellow oil. 
1
H NMR (300 MHz, CDCl3) δH (ppm): 1.64 (m, 6H, 2CH3 (Et-ester, keto and enol forms)); 1.99 
(s, 3H, CH3 (b)); 2.11 (s, 3H, CH3 (a)); 2.18 (s, 6H, 2CH3 (c)); 2.80 (d, 2H, CH2 (e)); 3.20 (s, 2H, 
CH2 (d)); 4.03 (m, 4H, 2CH2 (f, keto and enol forms)). 
Ethyl 2-(1-(2-hydroxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl)acetate (7) 
 
A solution of 2-hydroxyethylhydrazine (0.84 mL, 12.39 mmol) in EtOH (20 mL) was added to a 
solution of compound 6 (2.23 g, 12.46 mmol) in EtOH (10 mL) at 0ºC and the mixture was 
stirred overnight at room temperature. The product was concentrated under reduced pressure 
and dried under vacuum. 
Yield: 89% (2.50 g) of a brown oily solid. 
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1
H NMR (400 MHz, CDCl3) δH (ppm): 1.15 (t, 3H, CH3 (Et-ester)); 2.13 (s, 6H, 2CH3 (Me2pz)); 
3.30 (s, 2H, CH2 (c)); 3.61 (q, 2H, CH2 (d)); 3.85 (t, 2H, CH2); 4.04 (m, 2H, CH2); 4.50 (s br, 1H, 
OH).  
Ethyl 2-(1-(2-bromoethyl)-3,5-dimethyl-1H-pyrazol-4-yl)acetate (8) 
 
Method 1 
PBr3 (1mL, 10.61 mmol) was added to a solution of compound 7 (1.00 g, 4.42 mmol) in toluene 
(30 mL) and the reaction mixture was heated under reflux overnight. The solvent was 
evaporated under reduced pressure and the residue extracted with an aqueous solution of 
NaHCO3 and chloroform. The organic phase was dried with MgSO4 and filtered, then 
concentrated under reduced pressure and dried under vacuum. 
Yield: 67% (0.86 g) of brownish oil. 
Method 2 
CBr4 (4.97 g, 14.99 mmol) and PPh3 (3.93 g, 14.98 mmol) were added to a solution of 
compound 7 (1.60 g, 7.07 mmol) in dry THF (50 mL) and the reaction mixture was stirred for 
48h. The precipitate was filtered off and the filtrate was concentrated under reduced pressure.  
The product was purified by SiO2 column chromatography (eluent: DCM (100-96%)/EtOH (0-
4%)). The final product was washed with Et2O and filtered to remove the O-PPh3. The filtrate 
was concentrated and dried under vacuum. 
Yield: 47% (0.96 g) of brownish yellow oil. 
 
1
H NMR (300 MHz, CDCl3) δH (ppm): 1.95 (t, 3H, CH3 (Et-ester)); 2.23 (s, 6H, 2CH3 (2Met-pz)); 
3.34 (s, 2H, CH2 (c)); 3.66 (t, 2H, CH2); 4.09 (q, 2H, CH2 (d)); 4.39 (t, 2H, CH2). 
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Tert-butyl 2-aminoethylcarbamate (9) 
 
A solution of Boc2O (7.00 g, 32.07 mmol) in dioxane (30 mL) was added drop wise to a solution 
of 1,2-diaminoethane (17 mL, 257 mmol) in dioxane (40 mL) and the reaction mixture was 
stirred for 22 h. The solvent was evaporated under reduced pressure and then water was added 
to the residue. The white precipitate formed was filtered off and the filtrate was extracted with 
chloroform. The organic phase was dried with Na2SO4, filtered and concentrated under reduced 
pressure. The final product was dried under vacuum. 
Yield: 84% (4.30 g) of colorless oil. 
1
H NMR (400 MHz, CDCl3) δH (ppm): 1.13 (s, 2H, NH2); 1.23 (s, 9H, 3CH3 (BOC)); 2.56 (t, 2H, 
CH2 (a)); 2.94 (t, 2H, CH2 (b)); 5.46 (s br, 1H, NH). 
Ethyl 2-(1-(2-(2-(tert-butoxycarbonylamino)ethylamino)ethyl)-3,5-dimethyl-1H-pyrazol-4-
yl)acetate (10) 
 
A solution of compound 8 (0.4 g, 1.38 mmol) in dry ACN (5 mL) was added drop wise to a 
suspension of compound 9 (0.33 g, 2.07 mmol), K2CO3 (0.19 g, 1.38 mmol) and KI (0.01 g, 0.07 
mmol) in dry ACN (10 mL), and the resulting mixture was heated overnight under reflux. The 
solid was filtered off and the filtrate was concentrated under reduced pressure. The product was 
purified by SiO2 column chromatography (eluent: chloroform (90%)/MeOH (10%)). 
Yield: 48% (0.24 g) of yellow oil. 
1
H NMR (400 MHz, CDCl3) δH (ppm): 1.10 (t, 3H, CH3 (Et-ester)); 1.30 (s, 9H, 3CH3 (BOC)); 
2.06 (s, 6H, 2CH3 (Me2pz)); 2.57 (t, 2H, CH2); 2.85 (t, 2H, CH2); 3.05 (t, 2H, CH2); 3.19 (s, 2H, 
CH2 (e)); 3.91 (t, 2H, CH2 (a)); 3.98 (q, 2H, CH2 (f)); 5.46 (s, 1H, NH).     
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Ethyl 2-(1-(2-(tert-butoxycarbonyl(2-(tert-butoxycarbonylamino)ethyl)amino)ethyl)-3,5-
dimethyl-1H-pyrazol-4-yl)acetate (11) 
 
To a stirring solution of compound 10 (0.47 g, 1.28 mmol) in dry THF (20 mL) at 0ºC was added, 
drop wise, a solution of Boc2O (0.30 g, 1.38 mmol) in dry THF (15 mL), and the resulting mixture 
was stirred overnight at room temperature. The solvent was evaporated under reduced 
pressure and the residue was extracted with an aqueous solution of Na2CO3 and chloroform. 
The organic phase was dried with Na2SO4, filtered and evaporated under reduced pressure. 
The final product was dried under vacuum.  
Yield: 93% (0.56 g) of yellow oil.  
1
H NMR (300 MHz, CDCl3) δH (ppm): 1.22 (t, 3H, CH3 (Et-ester)); 1.42 (s, 18H, 6CH3 (2BOC)); 
2.07 (m, 6H, 2CH3 (Me2pz)); 3.06 (m, 4H, 2CH2); 3.33 (s, 2H, CH2 (e)); 3.52 (t, 2H, CH2); 4.08 
(m, 4H, 2CH2 (f + a)). 
2-(1-(2-(tert-butoxycarbonyl(2-(tert-butoxycarbonylamino)ethyl)amino)ethyl)-3,5-dimethyl-
1H-pyrazol-4-yl)acetic acid (12) 
 
A solution of NaOH (0.58 g, 14.60 mmol) in water (15 mL) was added to a solution of compound 
11 (0.58 g, 1.23 mmol) in THF (15 mL) and the stirring mixture was heated overnight under 
reflux. The mixture was then neutralized with HCl 4M at 0ºC. THF was evaporated under reduce 
pressure and the product extracted with DCM. The organic phase was dried with Na2SO4, 
filtered, evaporated under reduced pressure and finally dried under vacuum. 
Yield: 92% (0.50 g) of a yellow solid.  
5. Experimental section 
[71] 
 
1
H NMR (400 MHz, CDCl3) δH (ppm): 1.38 (s, 18H, 6CH3 (2BOC)); 2.13 (s, 6H, 2CH3 (Me2pz)); 
2.99 (m, 4H, 2CH2); 3.29 (s, 2H, CH2 (e)); 3.48 (t, 2H, CH2); 4.07 (m, 2H, CH2 (a)); 5.03 (s br, 
1H, OH/NH); 5.18 (s br, 1H, NH). 
2,5-dioxopyrrolidin-1-yl 2-(1-(2-(tert-butoxycarbonyl(2-(tert-
butoxycarbonylamino)ethyl)amino)ethyl)-3,5-dimethyl-1H-pyrazol-4-yl)acetate (13) 
 
To a stirring solution of compound 12 (0.45 g, 1.02 mmol) in dry DCM (20 mL) at 0ºC was 
added NHS (0.14 g, 1.24 mmol). After 15 min at this temperature EDC (0.24 g, 1.24 mmol) was 
added and the reaction mixture was stirred for 72 h at room temperature. The product was then 
extracted with water and DCM. The organic phase was separated, dried with Na2SO4, filtered 
and concentrated under reduced pressure. The final product was dried under vacuum.  
Yield: 75% (0.41 g) of a yellow solid.  
1
H NMR (400 MHz, CDCl3) δH (ppm): 1.40 (s, 18H, 6CH3 (2BOC)); 2.16 (s, 6H, 2CH3 (Me2pz)); 
2.79 (s, 4H, 2CH2 (NHS)); 2.84 (m, 4H, 2CH2); 3.51 (t, 2H, CH2); 3.62 (s, 2H, CH2 (e)); 4.07 (m, 
2H, CH2 (a)).  
Ethyl 1-(2-hydroxyethyl)-1H-pyrazole-4-carboxylate (21) 
 
A solution of 2-hydroxyethylhydrazine (0.95 mL, 13.80 mmol) in EtOH (76 mL) was added drop 
wise to a solution of ethyl 2-formyl-3-oxopropanoate (2.00 g, 13.88 mmol) in EtOH (16 mL) at 
0ºC. The mixture was stirred for 40 h and the solvent was then evaporated under reduced 
pressure. The final product was dried under vacuum.  
Yield: 96% (2.45 g) of yellow oil. 
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1
H NMR (300 MHz, CDCl3) δH (ppm): 1.11 (t, 3H, CH3); 3.73 (t, 2H, CH2 (a/b)); 4.02 (m, 4H, 
2CH2 (c + a/b)); 4.56 (s br, 1H, OH); 7.64 (s, 1H, CH); 7.82 (s, 1H, CH). 
Ethyl 1-(2-bromoethyl)-1H-pyrazole-4-carboxylate (22) 
 
CBr4 (8.80 g, 26.65 mmol) and PPh3 (6.97 g, 26.57 mmol) were added to a solution of 
compound 21 (2.45 g, 13.30 mmol) in pre-dried THF (90 mL) at 0ºC and the mixture was stirred 
for 16 h. The solvent was evaporated under reduced pressure and the mixture was extracted 
with DCM and water. The organic phase was dried with Na2SO4, filtered and concentrated 
under reduced pressure. The product was purified by SiO2 column chromatography (eluent: 
gradient elution with Hexane (90-30%)/Acetyl acetate (10-70%)). 
Yield: 66% (2.17 g) of yellow solid. 
1
H NMR (300 MHz, CDCl3) δH (ppm): 1.32 (t, 3H, CH3); 3.72 (t, 2H, CH2 (a)); 4.26 (m, 2H, CH2 
(c)); 4.48 (t, 2H, CH2 (b)); 7.94 (s, 2H, 2CH). 
13
C NMR (100.61 MHz, CDCl3) δ (ppm): 14.25 (CH3); 29.52 (CH2); 53.82 (CH2); 60.21 (CH2); 
115.14 (C, pz); 133.53 (CH, pz); 141.82 (CH, pz); 183.07 (C=O). 
Ethyl 1-(2-(2-(tert-butoxycarbonylamino)ethylamino)ethyl)-1H-pyrazole-4-carboxylate (23)  
 
A solution of compound 22 (2.20 g, 8.90 mmol) in dry ACN (20 mL) was added drop wise to a 
stirring suspension of compound 9 (2.14 g, 13.35 mmol), K2CO3 (1.23 g, 8.90 mmol) and KI 
(0.07 g, 0.44 mmol) in dry ACN (40 mL), and the mixture was heated under reflux overnight. 
The solid was filtered off and the solvent was evaporated under reduced pressure. The product 
5. Experimental section 
[73] 
 
was purified by SiO2 column chromatography (eluent: gradient elution with DCM (100-
94%)/MeOH (0-6%)). 
Yield: 74% (2.15 g) of yellow oil.  
1
H NMR (300 MHz, CDCl3) δH (ppm): 1.30 (t, 3H, CH3 (Et-pz)); 1.37 (s, 9H, 3CH3 (BOC)); 2.68 
(t, 2H, CH2); 3.03 (t, 2H, CH2); 3.13 (t, 2H, CH2); 4.16 (t, 2H, CH2); 4.18 (m, 2H, CH2 (e)); 4.98 (s 
br, 1H, NH); 7.85 (s, 2H, 2CH). 
Tert-butyl 2-(2-(4-(hydroxymethyl)-1H-pyrazol-1-yl)ethylamino)ethylcarbamate (24) 
 
LiAlH4 1 M/THF (1.50 mL, 1.50 mmol) was added drop wise to a solution of compound 23 (0.20 
g, 0.61 mmol) in dry THF (30 mL) at 0ºC and the mixture was stirred overnight at room 
temperature. Cold water (3 mL) was slowly added at 0ºC and after 5 min stirring at the same 
temperature, NaOH 10% (0.5 mL) was added.  The white precipitate formed was filtered off, 
while the filtrate was concentrated under reduced pressure and extracted with DCM. The 
organic phase was dried with Na2SO4, filtered and concentrated under reduced pressure. The 
product was purified by SiO2 column chromatography (eluent: gradient elution with chloroform 
(100-95%)/MeOH (0-5%)). 
Yield: 50% (0.09 g) of a yellow oil.  
1
H NMR (400 MHz, CDCl3) δH (ppm): 1.40 (s, 9H, 3CH3 (BOC)); 2.51 (m, 2H, CH2); 3.03 (m, 
2H, CH2); 3.19 (m, 2H, CH2); 4.18 (t, 2H, CH2); 4.50 (s, 2H, CH2 (e)); 7.43 (s, 2H, 2CH). 
ESI/MS (m/z) (C13H24N4O3) = [M
+ 
+ H] calculated 284.18, found 285.5. 
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Ethyl 1-(2-(tert-butoxycarbonyl(2-(tert-butoxycarbonylamino)ethyl)amino)ethyl)-1H-
pyrazole-4-carboxylate (25) 
 
A solution of Boc2O (1.25 g, 5.75 mmol) in THF (30 mL) was added drop wise to a solution of 
compound 23 (1.88 g, 5.75 mmol) in THF (30 mL) at 0ºC and the mixture was stirred overnight 
at room temperature. The solvent was evaporated under reduced pressure and the mixture was 
extracted with chloroform and a saturated aqueous solution of Na2CO3. The organic phase was 
dried with Na2SO4, filtered, concentrated under reduced pressure and the final product was 
dried under vacuum.  
Yield: 99% (2.44 g) of yellow oil 
1
H NMR (400 MHz, CDCl3) δH (ppm): 1.14 (t, 3H, CH3 (Et-pz)); 1.23 (s, 18H, 6CH3 (2BOC)); 
2.84 (m br, 4H, 2CH2); 3.45 (m br, 2H, CH2); 4.08 (m, 4H, 2CH2); 4.96 (s br, 1H, NH); 7.69 (s, 
2H, 2CH). 
13
C NMR (75.47 MHz, CDCl3) δ (ppm): 14.53 (CH3, Et-pz); 28.08 (9CH3, 2BOC); 39.09 (CH2); 
47.43 (CH2); 59.98 (2CH2); 79.60 (2C, 2BOC); 80.61 (CH2); 115.09 (C, pz); 134.90 (C-O, BOC); 
141.46 (2CH, pz); 162.86 (2C=O, BOC + Ester-pz). 
1-(2-(tert-butoxycarbonyl(2-(tert-butoxycarbonylamino)ethyl)amino)ethyl)-1H-pyrazol-4- 
hydroxymethyl (26) 
 
1 M LiAlH4 in THF (14.50 mL, 14.50 mmol) was added drop wise to a solution of compound 25 
(2.43 g, 5.68 mmol) in THF (30 mL) at 0ºC and the mixture was stirred overnight at room 
temperature. Cold water (15 mL) was slowly added at 0ºC and after 5 min stirring at the same 
temperature, NaOH 10% (2 mL) was added.  The white precipitate formed was filtered off and 
5. Experimental section 
[75] 
 
the filtrate was concentrated under reduced pressure. The mixture was extracted with diethyl 
ether and then with chloroform. The combined organic phase was dried with Na2SO4, filtered 
and concentrated under reduced pressure. The final product was dried under vacuum.  
Yield: 54% (1.18 g) of a yellow oil 
1
H NMR (400 MHz, CDCl3) δH (ppm): 1.26 (s, 18H, 6CH3 (2BOC)); 2.84 (m br, 4H, 2CH2); 3.43 
(m br, 2H, CH2); 4.05 (m br, 2H, CH2); 4.37 (s, 2H, CH2 (e)); 5.06 (s br, 1H, OH/NH); 5.28 (s br, 
1H, OH/NH); 7.19 (s, 1H, CH); 7.32 (s, 1H, CH). 
13
C NMR (85.47 MHz, CDCl3) δ (ppm): 28.92 (9CH3, 2BOC); 39.16 (CH2); 48.79 (CH2); 55.95 
(2CH2); 79.68 (2C, 2BOC); 80.88 (CH2); 121.97 (C, pz); 129.28 (C=O, BOC); 139.34 (2CH, pz); 
165.84 (C=O, BOC). 
(1-trityl-1H-pyrazol-4-yl)methanol (27) 
 
1 M LiAlH4  in THF (5.8 mL, 5.8 mmol) was added drop wise to a solution of compound ethyl 1-
trityl-1H-pyrazole-4-carboxylate (2.90 g, 7.58 mmol) in dry THF (55 mL) at 0ºC and the mixture 
was stirred overnight at room temperature. Cold water (2 mL) was slowly added at 0ºC and after 
5 min stirring at the same temperature, NaOH 10% (0.53 mL) was added.  The precipitate 
formed was filtered off and the filtrate was concentrated under reduced pressure and extracted 
with DCM. The organic phase was dried with Na2SO4, filtered, concentrated under reduced 
pressure and the final product was dried under vacuum.  
Yield: 84% (2.15 g) of a white solid 
1
H NMR (300 MHz, CDCl3) δH (ppm): 4.35 (s, 2H, CH2); 4.53 (s br, 1H, OH); 7.21 (m, 12H, 12 
CH (Tr)); 7.36 (m, 3H, 3CH (Tr)); 7.73 (s, 2H, 2CH (2CH-pz)). 
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4-(bromomethyl)-1-trityl-1H-pyrazole (28) 
 
PBr3 (0.11 mL, 1.17 mmol) was added to a stirring solution of compound 27 (0.58 g, 1.70 mmol) 
in toluene (9 mL) and the reaction mixture was heated under reflux overnight. The solvent was 
then evaporated under reduced pressure and the residue extracted with an aqueous solution of 
NaHCO3 and chloroform; the organic phase was dried in Na2SO4, filtered, concentrated under 
reduced pressure and the final product was dried under vacuum. 
Yield: 82% (0.56 g) of a white solid 
1
H NMR (300 MHz, CDCl3) δH (ppm): 4.52 (s, 2H, CH2); 7.16 (m, 6H, 6CH (Tr)); 7.25 (m, 9H, 
9CH (Tr)); 7.69 (s, 2H, 2CH (2CH-pz)). 
5.3.2 Synthesis and characterization of the DNA-binding units 
Anthracen-9-ylmethanol (1) 
 
To a stirring solution of 9-anthracene aldehyde (5.00 g, 24.24 mmol) in THF (25 mL) was added 
drop wise, a solution of NaBH4 (1.00 g, 26.43 mmo) in THF (10 mL) and the mixture was heated 
under reflux for 5 h.  The solvent was evaporated under reduced pressure. HCl 37% (25 mL) 
and water (50 mL) with crushed ice (25 g) were added to the residue and the suspension was 
stirred for 15 min. The precipitate was filtered and dried under vacuum. 
Yield: 80% (4.04 g) of yellow solid. 
5. Experimental section 
[77] 
 
1
H NMR (300 MHz, CDCl3) δH (ppm): 5.58 (s, 1H, OH); 5.67 (s, 2H, CH2); 7.49 (m, 4H, 4CH (b + 
c)); 8.03 (d, 2H, 2CH (a/d)); 8.42 (m, 3H, 3CH (e + a/d)).  
9-(bromomethyl)anthracene (2) 
 
Liquid Br2 (0.64 mL, 12.43 mmol) and compound 1 (2.50 g, 12.00 mmol) were added, slowly, to 
a suspension of PPh3 (3.30 g, 12.58 mmol) in dry ACN (60 mL) and the mixture was stirred for 2 
h at 0ºC. The precipitate was filtered and dried under vacuum to afford the final product.  
Yield: 62% (2.03 g) of yellow solid. 
1
H NMR (300 MHz, CDCl3) δH (ppm): 5.52 (s, 2H, CH2); 7.45 (t, 2H, 2CH (b/c)); 7.58 (t, 2H, 2CH 
(b/c)); 7.80 (d, 2H, 2CH (a/d)); 8.26 (d, 2H, 2CH (a/d)); 8.47 (s, 1H, CH (e)). 
3-(anthracen-9-ylmethyl)pentane-2,4-dione (3) 
 
Distilled acetylacetone (0.24 mL, 2.34 mmol) was added to a suspension of NaH (0.06 g, 2.57 
mmol) in dry THF (30 mL) at 0ºC and the mixture was stirred for 2 h at room temperature. 
Compound 2 (0.63 g, 2.34 mmol) was added at 0ºC and the mixture was stirred for 40 min at 
this temperature and then overnight at room temperature. HCl 1 M (60 mL) was added at 0ºC 
and the compound was extracted to Et2O, dried with Na2SO4, filtered and evaporated under 
reduced pressure. The product was purified by SiO2 column chromatography (eluent: 
chloroform (100-99%)/MeOH (0-1%)). 
Yield: 67% (0.46 g) of yellow solid. 
1
H NMR (300 MHz, CDCl3) δH (ppm): 1.97 (s, 6H, 2CH3); 4.17 (d, 2H, CH2); 4.25 (t, 1H, CH (g)); 
7.45 (m, 4H, 4CH (b + c)); 8.05 (d, 2H, 2CH); 8.15 (d, 2H, 2CH); 8.40 (s, 1H, CH (e)). 
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3-(anthracen-9-yl)propan-1-amine (14) 
 
To a solution of 2-(anthracen-9-yl)acrylonitrile (0.45 g, 1.95 mmol) in dry Et2O (10 mL) was 
added LiAlH4 1M/THF (1.95 mL, 1.95 mmol). The stirring mixture was heated under reflux for 30 
min and then left at room temperature for 20 h. After this time, water (2 mL) was added followed 
by addition of an aqueous solution of NaOH 20% (0.76 mL) 5 min later.  The product was 
extracted with water and Et2O and the emulsion formed was washed with more Et2O. The 
combined organic phase was dried with Na2SO4, filtered, concentrated under reduced pressure 
and the product dried under vacuum.  
Yield: 96% (0.44 g) of brown oily solid. 
1
H NMR (300 MHz, CDCl3) δH (ppm): 1.70 (s br, 2H, NH2); 1.93 (m, 2H, CH2 (g)); 2.89 (t, 2H, 
CH2 (f/h)); 3.62 (t, 2H, CH2 (f/h)); 7.45 (m, 4H, 4CH (b + c)); 7.56 (d, 2H, 2CH (a/d)); 8.03 (m, 
3H, 3CH (e + a/d)). 
2-(3-bromopropyl)isoindoline-1,3-dione (15) 
 
To a stirring solution of potassium phthalimide (12.70 g, 68.56 mmol) in dry ACN was added 1,3 
dibromopropane (20 mL, 197.00 mmol) and the mixture was heated under reflux for 6h.  The 
precipitate was filtered off and the filtrate was partially concentrated under reduced pressure 
and left in the fridge for 72 h. The precipitate formed was filtered and washed with cold MeOH. 
The MeOH was left in the fridge until a crystalline precipitate was formed. The latter was 
separated and dried under vacuum.  
Yield: 69% (12.68 g) of a yellow solid 
1
H NMR (300 MHz, CDCl3) δH (ppm): 2.24 (m, 2H, CH2 (d)); 3.40 (t, 2H, CH2); 3.80 (t, 2H, CH2); 
7.73 (m, 2H, 2 CH); 7.84 (m, 2H, 2CH). 
5. Experimental section 
[79] 
 
2-(3-iodopropyl)isoindoline-1,3-dione (16) 
 
KI (3.13 g, 18.86 mmol) was added to a stirring solution of compound 15 (3.00 g, 11.19 mmol) 
in pre-dried acetone (60 mL) and the mixture was heated under reflux for 48 h. The solid was 
filtered off and the filtrate was concentrated under reduced pressure and dried under vacuum.    
Yield: 94% (3.33 g) of a yellow solid. 
1
H NMR (300 MHz, CDCl3) δH (ppm): 2.25 (m, 2H, CH2 (d)); 3.17 (t, 2H, CH2 (e)); 3.77 (t, 2H, 
CH2 (c)); 7.73 (m, 2H, 2 CH); 7.84 (m, 2H, 2CH).  
3,6-bis(dimethylamino)-10-(3-(1,3-dioxoisoindolin-2-yl)propyl)acridinium (17) 
 
Acridine orange (0.63 g, 2.37 mmol) and a pinch of NaHCO3 were added to a solution of 
compound 16 (1.50 g, 4.76 mmol) in anhydrous p-xylene (30 mL) and the stirring mixture was 
heated under reflux for 70 h. The precipitate was filtered, washed with Et2O and dried under 
vacuum.  
Yield: 91% (1.26 g) of brownish red solid. 
1
H NMR (400 MHz, CDCl3) δH (ppm): 2.63 (m, 2H, CH2 (d)); 3.47 (m, 12H, 4CH3); 4.24 (t, 2H, 
CH2); 4.97 (t, 2H, CH2); 6.89 (s, 2H, 2CH (f)); 7.47 (d, 2H, 2CH); 8.06 (m, 6H, 6CH); 8.87 (s, 1H, 
CH (i)).  
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10-(3-aminopropyl)-3,6-bis(dimethylamino)acridinium (18) 
 
Hydrazine monohydrate (0.69 mL, 14.00 mmol) was added to a solution of compound 17 (0.60 
g, 1.03 mmol) in MeOH (30 mL) and the stirring mixture was heated under reflux for 24 h. HCl 
37% was added until a white precipitate was formed. The latter was filtered off and the filtrate 
was alkalized to pH 12 with an aqueous solution of NaOH 4M. The solvent was evaporated 
under reduced pressure and the residue extracted with water and chloroform. The organic 
phase was dried with Na2SO4, filtered and concentrated under reduced pressure. The final 
product was dried under vacuum. 
Yield: 37% (0.17 g) 
1
H NMR (300 MHz, CD3OD) δH (ppm): 1.18 (m, 2H, NH2); 2.14 (m, 2H, CH2 (f)); 2.99 (t, 2H, CH2 
(g)); 3.31 (m, 12H, 4CH3); 4.79 (t, 2H, CH2 (e)); 6.77 (s, 2H, 2CH (a)); 7.26 (d, 2H, 2CH (b/c)); 
7.90 (d, 2H, 2CH (b/c)); 8.67 (s, 1H, CH (d)). 
5.3.3 Synthesis and characterization of Ant-CH2-pzNN (L1) 
2-(4-(anthracen-9-ylmethyl)-3,5-dimethyl-1H-pyrazol-1-yl)ethanol (4) 
 
A solution of 2-hydroxyethyl hydrazine (0.11 mL, 1.63 mmol) in EtOH (8mL) was added drop 
wise to a solution of compound 3 (0.46 g, 1.57 mmol) in a mixture of chloroform and EtOH (1:1) 
(8 mL) at 0ºC. The mixture was stirred for 5 h at room temperature and the solvent was then 
evaporated under reduced pressure and the product dried under vacuum. 
5. Experimental section 
[81] 
 
Yield: 69% (0.36 g) of a yellow solid. 
1
H NMR (300 MHz, CDCl3) δH (ppm): 1.71 (s, 3H, CH3 (Mepz)); 1.92 (s, 3H, CH3 (Mepz)); 4.19 
(t, 2H, CH2 (g/h)); 4.31 (t, 2H, CH2 (g/h)); 4.73 (s, 2H, CH2 (f)); 4.98 (s br, 1H, OH); 7.47 (m, 4H, 
4CH (b + c)); 8.06 (m, 4H, 4CH (a + d)); 8.45 (s, 1H, CH (e)). 
4-(anthracen-9-ylmethyl)-1-(2-bromoethyl)-3,5-dimethyl-1H-pyrazole (5) 
 
PBr3 (0.08 mL, 0.83 mmol) was added to a stirring solution of compound 4 (0.15 g, 0.45 mmol) 
in pre-dried toluene (8 mL) and the mixture was heated under reflux overnight. The solution was 
washed with a saturated aqueous solution of NaHCO3 and then with water. The organic phase 
was separated, dried with Na2SO4, filtered and concentrated under reduced pressure. The final 
product was dried under vacuum.  
Yield: 59% (0.11 g) of a yellow solid. 
1
H NMR (300 MHz, CDCl3) δH (ppm): 1.65 (s, 3H, CH3 (Mepz)); 1.89 (s, 3H, CH3 (Mepz)); 3.58 
(t, 2H, CH2 (g/h)); 4.23 (t, 2H, CH2 (g/h)); 4.70 (s, 2H, CH2 (f)); 7.44 (m, 4H, 4CH (b + c)); 8.19 
(m, 2H, 2CH (a/d)); 8.28 (m, 2H, 2CH (a/d)); 8.43 (s, 1H, CH (e)). 
N
1
-(2-(4-(anthracen-9-ylmethyl)-3,5-dimethyl-1H-pyrazol-1-yl)ethyl)ethane-1,2-diamine (L1) 
 
A solution of compound 5 (0.11 g, 0.27 mmol) in dry MeOH (5 mL) was added drop wise to a 
stirring solution of 1,2-diaminoethane (0.32 mL, 4.80 mmol) in MeOH (20 mL) and the mixture 
was heated under reflux overnight. The solvent was evaporated under reduced pressure and 
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the compound was extracted with chloroform and water. The organic phase was separated, 
dried with Na2SO4, filtered and concentrated under reduced pressure. The product was purified 
by SiO2 column chromatography (eluent: gradient elution with MeOH (100-96%)/ NH4OH(0-
4%)). 
Yield: 21% (0.02 g) of yellow oily solid. 
1
H NMR (300 MHz, CDCl3) δH (ppm): 1.58 (s, 6H, 2CH3 (2Met-pz)); 2.58 (t, 2H, CH2 (h/i/j)); 2.66 
(t, 2H, CH2 (h/i/j)); 2.89 (t, 2H, CH2 (h/i/j)); 3.95 (t, 2H, CH2 (g)); 4.67 (s, 2H, CH2 (f)); 7.43 (m, 
4H, 4CH (b + c)); 7.99 (m, 2H, 2CH (a/d)); 8.13 (m, 2H, 2CH (a/d)); 8.30 (s, 1H, CH (e)). 
HPLC: tR (column A; method A) = 21.04 min 
5.3.4 Synthesis and characterization of Ant-(CH2)3-pzNN (L2) 
2-(1-(2-(2-tert-butoxycarbonyl(2-(tert-butoxycarbonylamino)ethyl)amino)ethyl)-3,5-
dimethyl-1H-pyrazol-4-yl)-N-(3-(anthracen-9-yl)propyl)acetamide (19) 
 
DIPEA (0.17 mL, 0.98 mmol) was added to a stirring solution of compound 14 (0.10 g, 0.43 
mmol) in dry DCM followed by a slow addition of a solution of compound 13 in dry DCM and the 
mixture was stirred for 70 h. The compound was extracted with DCM and water.  The organic 
phase was separated, dried with Na2SO4, filtered and concentrated under reduced pressure. 
The final product was dried under vacuum. 
Yield: 70% (0.20 g) of a yellow oily solid 
1
H NMR (300 MHz, CDCl3) δH (ppm): 1.25 (m, 22H, 6CH3 (2BOC) + 2 CH2); 2.11 (m, 6H, 2CH3 
(2Met-pz)); 3.05 (m, 2H, CH2); 3.27 (s, 2H, CH2 (e)); 3.38 (m, 2H, CH2); 3.46 (m, 2H, CH2); 3.60 
(m, 2H, CH2); 4.05 (m, 2H, CH2); 7.38 (m, 4H, 4CH (j + k)); 7.95 (d, 2H, 2CH (i/l)); 8.20 (m, 3H, 
3CH (m + i/l)). 
5. Experimental section 
[83] 
 
2-(1-(2-(2-aminoethylamino)ethyl)-3,5-dimethyl-1H-pyrazol-4-yl)-N-(3-(anthracen-9-
yl)propyl)acetamide (L2) 
 
TFA (1.8 mL, 23.50 mmol) was added to a solution of compound 19 (0.20 g, 0.30 mmol) in DCM 
(2 mL) and the mixture was stirred overnight. The product was dried under vacuum.  
Yield: 87% (0.14 g) of a yellow oily solid 
1
H NMR (300 MHz, CDCl3) δH (ppm): 1.19 (m, 2H, NH2); 1.85 (m, 4H, 2CH2); 2.15 (s, 3H, CH3 
(Met-pz)); 2.57 (m, 3H, CH3 (Met-pz)); 2.89 (t, 2H, CH2); 3.22 (s, 2H, CH2 (e)); 3.38 (q, 2H, CH2); 
3.55 (t, 2H, CH2); 4.04 (t, 2H, CH2); 5.76 (d br, 1H, NH); 7.42 (m, 4H, 4CH (j + k)); 7.98 (d, 2H, 
2CH (i/l)); 8.13 (d, 2H, 2CH (i/l)); 8.26 (s, 1H, CH (m)). 
HPLC: tR (column A; method A) = 21.99 min 
5.3.5 Synthesis and characterization of AO-(CH2)3-pzNN (L3) 
10-(3-(2-(1-(2-(tert-butoxycarbonyl(2-(tert-butoxycarbonylamino)ethyl)amino)ethyl)-3,5-
dimethyl-1H-pyrazol-4-yl)acetamido)propyl)-3,6-bis(dimethylamino)acridinium (20) 
 
A solution of compound 18 (0.06 g, 0.13 mmol) in dry DMF was stirred for 1 hour, and then 
DIPEA (35 µL, 0.20 mmol) was added followed by a slow addition of a solution of compound 13 
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(0.07 g, 0.13 mmol) in dry DMF. The mixture was stirred for 96 h. The solvent was evaporated 
under vacuum and a dry final product was obtained.  
Yield: 86% (0.10 g) of a brownish oily solid 
1
H NMR (300 MHz, CD3OD) δH (ppm): 1.44 (m, 22H, 6CH3 (2BOC) + 2CH2); 2.23 (m, 6H, 2CH3 
(Met-pz)); 3.02 (s, 12H, 4CH3 (AO)); 3.53 (m br, 6H, 3CH2); 4.14 (m br, 4H, 2CH2); 4.65 (m br, 
2H, CH2); 6.62 (s br, 2H, 2CH (i)); 7.18 (m br, 2H, 2CH (j/k)); 7.84 (m br, 2H, 2CH (j/k)); 8.59 (s 
br, 1H, CH (l)). 
10-(3-(2-(1-(2-(2-aminoethylamino)ethyl)-3,5-dimethyl-1H-pyrazol-4-yl)acetamido)propyl)-
3,6-bis(dimethylamino)acridinium (L3) 
 
HCl 37 % (2 mL) was added to a solution of compound 20 (0.10 g, 0.12 mmol) in MeOH (5 mL) 
at 0ºC and the mixture was stirred for 18 h at room temperature. The pH was adjusted to 12 
with an aqueous solution of NaOH 2.5 M and the mixture was extracted with chloroform. The 
organic phase was separated, dried with Na2SO4, filtered and concentrated under reduced 
pressure. The product was purified by Al2O3 column chromatography (eluent: gradient elution 
with MeOH (100-96%)/ NH4OH (0-4%)). 
Yield: 16% (0.01 g) of a brownish red solid. 
1
H NMR (300 MHz, CD3OD) δH (ppm): 2.12 (m, 6H, 2CH3 (Me-pz)); 2.19 (m, 4H, 2CH2); 2.66 
(m, 2H, CH2); 2.92 (m, 2H, CH2); 3.13 (m, 2H, CH2); 3.32 (s, 12H, 4CH3 (AO)); 3.49 (m, 2H, 
CH2); 4.07 (m, 2H, CH2); 4.65 (m, 2H, CH2); 6.69 (s, 2H, 2CH (i)); 7.25 (d, 2H, 2CH (j/k)); 7.89 
(d, 2H, 2CH (j/k)); 8.66 (s, 1H, CH (l)). 
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5.4 Synthesis and characterization of the Re complexes 
5.4.1 fac-[Re(CO)3(Ant-CH2-pzNN)]Br (Re1) 
 
[Re(CO)5Br] (20 mg; 0.054 mmol) was reacted with Ant-CH2-pzNN (L1) (22 mg, 0.054 mmol) in 
MeOH and the reaction mixture was heated under reflux overnight. After removing the solvent 
under reduced pressure, the product was washed with hexane and dried under vacuum.  
Yield: 76% (30 mg) of brownish yellow solid.  
1
H NMR (300 MHz, CD3OD) δH (ppm): 3.09 (s, 3H, CH3 (Met-pz)); 3.64 (s, 3H, CH3 (Met-pz)); 
3.91 (t br, 2H, CH2 (h/i/j)); 4.27 (m br, 2H, CH2); 4.82 (t, 2H, CH2); 5.20 (m br, 2H, CH2); 6.23 (s, 
2H, CH2 (f)); 8.91 (m, 4H, 4CH (b + c)); 9.48 (d, 2H, 2CH (a/d)); 9.58 (d, 2H, 2CH (a/d)); 9.92 (s, 
1H, CH (e)). 
HPLC: tR (column A; method A) = 22.90 min 
5.4.2 fac-[Re(CO)3(Ant-(CH2)3-pzNN)]Br (Re2) 
 
[Re(H2O)3(CO)3]Br (49 mg; 0.12 mmol) was reacted with Ant-(CH2)3-pzNN (L2) (55 mg, 0.12 
mmol) in MeOH and the reaction mixture was heated under reflux overnight. After removing the 
solvent under reduced pressure, the product was washed with Et2O, then with CHCl3 and 
centrifuged. The final product (supernatant) was dried under vacuum.  
Yield: 62% (54 mg) of yellow solid.  
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1
H NMR (300 MHz, CD3OD) δH (ppm): 1.05 (m, 2H, CH2 (f)); 1.74 (m, 2H, CH2 (g)); 2.09 (s, 3H, 
CH3 (Met-pz)); 2.18 (m, 3H, CH3 (Met-pz)); 2.25 (m, 2H, CH2 (d)); 2.52 (m, 2H, CH2 (c)); 3.12 (s, 
2H, CH2 (e)); 3.22 (m, 2H, CH2 (h)); 3.55 (m, 2H, CH2 (b)); 4.50 (m, 2H, CH2 (a)); 7.20 (m, 4H, 
4CH (j + k)); 7.77 (d, 2H, 2CH (i/l)); 8.05 (d, 2H, 2CH (i/l)); 8.14 (s, 1H, CH (m)). 
13
C NMR (75.47 MHz, CD3OD) δ (ppm): 9.04 (CH3); 13.07 (CH3); 24.74 (CH2 (h)); 29.84 (CH2 
(f)); 30.64 (CH2 (g)); 39.57 (CH2 (e)); 41.91 (CH2 (d)); 48.45 (CH2 (b)); 48.55 (CH2 (a)); 54.51 
(CH2 (c)); 112.75 (C); 123.77 (CH); 124.52 (CH); 125.34 (CH); 125.50 (C); 126.02 (C); 126.08 
(C); 126.35 (C); 126.64 (CH); 127.59 (C); 127.88 (C); 128.12 (C); 128.92 (CH); 129.43 (CH); 
131.73 (CH); 133.57 (CH); 134.03 (CH); 142.34 (C3/C5-pz); 152.13 (C3/C5-pz); 171.52 (C=O); 
194.82 (CO). 
HPLC: tR (column A; method A) = 24.12 min 
ESI/MS (m/z) (C31H35N5O4Re) = [M
+
] calculated 728.22, found 728.5 (100%). 
5.5 Synthesis and characterization of the 99mTc complexes 
5.5.1 Precursor fac-[99mTc(H2O)3(CO)3]
+ 
 
Sodium pertechnetate (Na[
99m
TcO4]), typically with activity of ca. 400 mCi, was obtained in 
sealed vials under vacuum after elution of a 
99
Mo/
99m
Tc generator (ELUMATIC III®) with a 
solution of NaCl 0.9% (5 mL). fac-[
99m
Tc(H2O)3(CO)3]
+
 was prepared by adding the Na[
99m
TcO4] 
eluate (3mL) to a lyophilized Isolink® kit (Covidien, Petten) under N2 atmosphere. The mixture 
was heated to 100 ºC for 30 min in dry bath and then neutralized with a solution of HCl 1M (145 
µL) at room temperature. The organometallic precursor was obtained with an activity of c.a. 200 
mCi. The radiochemical purity was evaluated by HPLC.  
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5.5.2 fac-[99mTc(CO)3(Ant-CH2-pzNN)]
+ (Tc1) 
 
A solution of Ant-CH2-pzNN (L1) in EtOH (750 µL, 1x10
-3 
M)
 
was added to an empty sealed vial 
under N2 atmosphere. A solution of the precursor fac-[
99m
Tc(H2O)3(CO)3] (750 µL) was added to 
the vial, leading to a final ligand concentration of  5x10
-4 
M. 
 
The mixture was heated to 80 ºC for 
30 min in a dry bath. Typically the complex was synthesized with activities of ca. 20 mCi. The 
analytical control and purification were performed by HPLC. The purified complex was usually 
recovered with activities of ca. 10 mCi. 
HPLC: tR (column B; method B) = 24.29 min 
5.5.3 fac-[99mTc(CO)3(Ant-(CH2)3-pzNN)]
+ (Tc2) 
 
A solution of Ant-(CH2)3-pzNN (L2) in EtOH (50 µL, 1x10
-2 
M)
 
was added to an empty sealed vial 
under N2 atmosphere. A solution of the precursor fac-[
99m
Tc(H2O)3(CO)3] (950 µL) was added to 
the vial, leading to a final ligand concentration of  5x10
-4 
M.
 
The mixture was heated to 100 ºC 
for 30 min in dry bath. Typically the complex was synthesized with activities of ca. 20 mCi. The 
analytical control and purification were performed by HPLC. The purified complex was usually 
recovered with activities of ca. 10 mCi.  
HPLC: tR (column B; method B) = 23.53 min 
Log (Po/w) = 2.62 ± 0.19 
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5.6 Spectroscopic studies of the interaction of the ligands and Re 
complexes with the DNA molecule 
These studies were performed at IST, Lisbon, with the collaboration of Dr. Sofia Gama (CR 
Group, C
2
TN). 
The DNA sodium salt from calf thymus (CT) DNA (1mg, Sigma) was dissolved  in PBS (10 mM, 
pH = 7.2) (1 mL) overnight then quantified per nucleotide, after adequate dilution with the buffer, 
by absorption spectroscopy at 260 nm (ε260nm = 6600 M
-1
cm
-1
).
67
 The solutions of the ligand and 
Re complex were prepared with DMSO and its concentrations were kept constant while the 
concentration of the CT-DNA was varied at each measurement during the titrations. All the 
measurements were carried out in PBS (10 mM, pH = 7.2). To obtain the intrinsic binding 
constant (K) all calculations were done by considering the DNA concentration in base pairs, and 
the data were corrected for volume changes. 
UV-visible spectroscopy 
The UV-Vis spectra were recorded on a Perkin Elmer Lambda 35 UV-vis spectrometer, using 
quartz cuvettes (1cm). Equivalent amounts of the CT-DNA solution were added to the sample 
and reference (PBS) to eliminate possible interferences of DNA absorbance in the region of 
absorbance of the chromophores, and the mixtures were allowed to equilibrate after each 
addition. The UV-Vis spectra were recorded until no further changes in the absorbance were 
observed.  
Fluorescence spectroscopy 
The fluorescence spectra were recorded on a Perkin Elmer LS 55 fluorescence spectrometer, 
using quartz cuvette (1cm). After each addition of CT-DNA suspension, the mixture was allowed 
to equilibrate and the absorption at the excitation wavelength was recorded. The ligand and 
corresponding Re complex were excited at 320 nm and the emission spectra were recorded 
from  = 350 - 550 nm, with a scan speed of 300 nm min
-1
. Emission and excitation slits were 
chosen in order to maximize the fluorescence intensity. The fluorescence spectra were 
recorded until there were no further changes in the fluorescence intensity.  
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5.7 In vitro studies of the 99mTc-Ant-(CH2)3-pzNN (Tc2) 
5.7.1 Lipophilicity 
The lipophilicity of the 
99m
Tc complex Tc2 was evaluated by determining its partition-
coefficient (logP) in a biphasic system n-octanol/PBS 0.1M (pH=7.4): 
To three polyethylene vials were added n-octanol (1 mL) and PBS 0.1M (pH=7.4) (1 mL) and 
the mixtures were vortexed for 1 min. Then, a solution of purified complex Tc2 (25 µL) was 
added to each vial and vortexed again, followed by centrifugation at 3000 rpm for 5 min.  With 
the aqueous and organic phases well separated, small aliquots (100 µL x three replicates) of 
each phase were removed to new vials and the activities were measured in a Gamma counter. 
The log Po/w was calculated by applying the following expression: 
log (Po/w)  = log 
 Activity in the organic phase (cpm)
Activity in the aqueous phase (cpm)
x 100 
5.7.2 In vitro stability 
5.7.2.1 Stability in the presence of histidine 
A solution of complex Tc2 (100 µL) was added to a solution of histidine (900 µL, 1x10
-3
M) in 
PBS 0.1 M (pH=7). The mixture was incubated at 37 ºC in water bath and analyzed by HPLC 
after 1 and 2 h.  
5.7.2.2 Stability in Human serum and determination of protein binding 
A solution of complex Tc2 (100 µL) was added to a polyethylene vial containing human serum 
(500 µL) and the mixture was incubated at 37 ºC in water bath. A small aliquot (100 µL) of the 
mixture was collect to an eppendorf after 1, 2, 3 and 6 h incubating. The aliquot was treated 
with EtOH (200 µL) and centrifuged at 3000 rpm for 15 min. The supernatant was separated 
and analyzed by HPLC. The pellet was washed with EtOH and centrifuged again, then 
separated and its activity was measured in an ionization chamber. The activity present in the 
pellet estimates the proportion of the complex associated to proteins by the following 
expression: 
Multifunctional Organometallic Compounds for Auger Therapy  
 
 
 
[90] 
 
Protein-binding (%) =
 Activity in the pellet  
Activity in the supernatant 
x 100 
5.8 Cell studies  
These studies were performed with the collaboration of Dr. Paula Raposinho (CR group, C
2
TN). 
5.8.1 Cell lines and cultures 
B16-F1 murine melanoma cells (European Collection of Cell Cultures, UK) were grown in 
Dulbecco’s Modified Eagle Medium (DMEM) containing Glutamax-I (Gibco, Invitrogen). 
PC-3 human prostate cancer cells (American Type Culture Collection, USA) were grown in 
Roswell Park Memorial Institute medium (RPMI 1640) containing L-glutamine (Gibco, Introgen). 
Both mediums were supplemented with 10% of heat inactivated fetal bovine serum (FBS) and 
1% of antibiotic solution (penicillin:streptomycin) (all from Gibco, Invitrogen) and were changed 
every two days. The cell lines were incubated in a humidified atmosphere of 95% air and 5% 
CO2 at 37°C. When confluent in a monolayer, the adherent cells would be detached after 
treatment with trypsin-EDTA (Gibco, Invitrogen) and seeded in new cell culture flasks. 
5.8.2 Cell internalization of the 99mTc complexes 
The cells of each cell lines were seeded into 24-well tissue culture plates (2x10
5
 cells/500 µL of 
culture medium per well) and allowed to attach overnight at 37°C.  
The solution of the purified 
99m
Tc complex in PBS 0.1 M (pH=7) was diluted to the intended final 
activity value, in the assay medium MEM containing 0.2% BSA (Bovine Serum Albumin) and 
HEPES 25 mM (N-(2-hydroxyethyl)piperazine-N’-ethanesulfonic acid).  
After removing the culture medium of each well, small aliquots (500 µL) of the radioactive 
solution were added to the attached cells. The cells were incubated in a humidified atmosphere 
of 95% air and 5% CO2 at 37°C and the studies proceeded for an incubation period of 5 min to 4 
hours. For each time point, the unbound radioactive compound of four wells (4 replicates) were 
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removed; the cells were washed with cold assay medium and then, twice, with glicine/HCl buffer 
pH 2.8 (500 µL) for 4 min at room temperature to remove the possible cell-surface bound 
radiocompounds. The buffer washes were separated and its activities measured. The pH of the 
cells was then neutralized with cold PBS containing 0.2% BSA, followed by lysis with NaOH 1M 
(500 µL) at 37°C for 10 min. The lysates were separated and its activity measured to determine 
the total of internalized radiocompounds. 
% Cell internalization = 
 Lysates activity (cpm)
Total  added activity (cpm)
 x 100 
% Surface bound = 
 Glicine/HCl buffer whashes activity (cpm)
Total  added activity (cpm)
 x 100 
% Total cell uptake = Internalization  (%) + Surface bound (%) 
5.8.3 Cellular and nuclear uptake of the 99mTc complexes 
The 24-well tissue culture plates were prepared, treated with the radioactive solution and 
incubated as described in the previous section. At each giving time, the cells of each four 
replica wells were washed with PBS (250 µL) containing 2% BSA and detached with trypsin 
(100 µL) at 37°C for a few minutes. DMEM medium (250 µL) was added to inactivate trypsin 
and the suspension was transferred to an eppendorf to be centrifuged at 800 rpm for 2 min. The 
supernatant was removed and the pellet was washed and centrifuged, twice, with PBS (250 µL) 
containing 2% BSA at 4°C. The pellet was resuspended in lysis buffer (10 mM Tris, 1.5 mM 
MgCl2, 140 mM NaCl) (500 µL) with Nonidet (P-40 0.02%, pH 8.0-8.3) (1 µL) to disrupt the cell 
membrane. After 15 min incubation on ice the suspension was centrifuged at 1300 g for 1 min 
at 4°C. The activities of the supernatant (extra-nuclear) and pellet (nuclear) were measured 
separately.  
% Nuclear uptake = 
Pellet activity (cpm)
Total added activity (cmp)  
 x 100 
% Cell uptake = 
Supernatant activity (cpm) + Pellet activity (cpm)
Total added activity (cpm) 
 x 100 
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5.8.4 Mitochondrial and nuclear uptake of the 99mTc complexes 
PC3 and B16F1 adherent cells (T75 culture flask) were incubated with the purified 
99m
Tc-
complexes (about 300 µCi/2 mL of culture medium) for 2h at 37ºC. The harvested cell 
suspension was centrifuged at 850 g for 2 min and cells washed with PBS to remove the 
unbound radioactive compound. The activity of the pellet was measured to allow the 
determination of cellular uptake.  
 
The mitochondria (and nucleus) were isolated from PC3 and B16-F1 cells using the commercial 
kit Mitochondria Isolation Kit for Cultured Cells (Thermo Scientific) as instructed on the 
manufacturer's protocol, by Reagent-based method. Briefly, the pellet (about 2 x 10
7 
cells) was 
treated with Mitochondria Isolation Reagent  A supplemented with a protease inhibitors cocktail 
(800 µL), vortexed at medium speed for 5 seconds and incubated on ice for 2 min. Mitochondria 
Isolation Reagent B (10 µL) was added and the mixture was vortexed at maximum speed for 5 
seconds, incubated on ice and vortexed every minute for 5 min. Mitochondria Isolation Reagent 
C supplemented with a protease inhibitors cocktail (800 µL) was then added and the 
suspension was centrifuged for 10 min at 700 g at 4°C. The activity of the pellet (nuclear 
fraction) was measured. The supernatant was centrifuged for 15 min at 3000 g at 4°C to remove 
the lysosomal and peroxisomal contaminants. The pellet, containing the isolated mitochondria, 
was again treated with Mitochondria Isolation Reagent C (500 µL) and centrifuged for 5 min at 
12,000 g. The supernatant was discarded and the activity of the mitochondria pellet was count. 
%Nuclear uptake =
Nuclear Pellet activity (cpm)
Total added activity (cmp) 
 x 100 
% Mitochondrial uptake =
Mitochondrial Pellet activity (cpm)
Total added activity (cmp)  
 x 100 
5.8.5 Radio-Cytotoxicity of the 99mTc complexes  
PC3 and B16-F1 cells were seeded into 96-well tissue culture plates (9x10
3
 cells/200 µL of 
culture medium per well) and allowed to attach overnight at 37°C.  
Several solutions of the purified 
99m
Tc-complex (in PBS 0.1 M, pH=7) with different activities 
were prepared by successive dilution in DMEM complete medium.  
The radioactive solutions (200 µL) were added to the cells in order to get eight replicas for each 
activity. Cells exposed to only DMEM complete medium and [
99m
TcO4]
-
 in DMEM complete 
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medium were used as control.  The cells were incubated in a humidified atmosphere of 95% air 
and 5% CO2 at 37°C for 36-40 hours.  
At the end of the incubation period, the compounds were removed and cells were washed with 
PBS (200 μL). Cell viability was then determined by incubating cells with 200 μL of MTT solution 
(0.5 mg/mL in PBS). After 3 h at 37°C/5% CO2, the solution was removed and the purple 
formazan crystals formed inside the cells were dissolved in DMSO (200 μL) by thorough 
shaking. The absorbance at 570 nm was measured using a microplate spectrophotometer 
(PowerWave Xs, Bio-Tek Instruments, Winooski, VT, USA). 
5.8.6 Cytotoxicity of the ligands and Re complexes 
PC3 and B16-F1 cells were seeded into 96-well tissue culture plates (9x10
3
 cells/200 µL of 
culture medium per well) and allowed to attach overnight at 37°C.  
A high concentrated (20 mM) solution of inactive ligands and Re-complexes was prepared in 
DMSO (stock solution). From the stock solution, solutions with concentrations ranging from 200 
µM to 0.1 µM were prepared by successive dilution in culture medium with 0.1% DMSO. The 
solutions (200 µL) were added to the cells (eight replicates for each concentration). The cells 
were incubated with the compounds in a humidified atmosphere of 95% air and 5% CO2 at 37°C 
for 36-40 hours. The effect of the vehicle solvent (DMSO) on the growth of these cell lines was 
evaluated in all experiments by exposing untreated control cells to both concentrations of 
DMSO used (0.2% and 0.1%). 
The cellular viability was determined by performing the MTT assay as described in the previous 
section. 
For each test compound and for each cell line, a dose−response curve was obtained. The 
cytotoxic effects of ligands and Re-complexes were quantified by calculating the compound 
concentration inhibiting tumor cell growth by 50% (IC50), based on non-linear regression 
analysis of dose–response data (GraphPad Prisma 5 software).  
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